



Cumulative Index 2003

Volume 87

January	PREOPERATIVE MEDICAL CONSULTATION, pages 1-302
March	THERAPEUTIC OPTIONS IN HEART FAILURE, pages 303-588
May	CASE STUDIES IN NEUROLOGY, PART I, pages 589-754
July	CASE STUDIES IN NEUROLOGY, PART II, pages 755-916
September	WOMEN'S HEALTH ISSUES, pages 917-1156
November	CONTEMPORARY THROMBOSIS DEBATES, pages 1157-1306

Note: Page numbers of article titles are in **boldface** type.

A

A-127722 (endothelin receptor antagonist),
myocardial remodeling and, 469

Abdominal pain, in porphyria, 718

ACE inhibitors. *See* Angiotensin-converting
enzyme inhibitors.

Acetaminophen, for migraine headache,
594

Acetazolamide, for Meniere's disease,
636-637

Acetylcholine, impaired action of, in CHF,
444

Acorn cardiac support device, for CHF,
545-546

Acoustic neuroma, dizziness in, 614-615

Acquired immunodeficiency syndrome.
See Human immunodeficiency
virus infection.

Actigraphy, in sleep disorders, 809

Acupuncture, for hot flashes, 1108

Acute retroviral syndrome, in women,
974-975

Acyclovir
for Bell's palsy, 702
for herpes zoster, 699

Adeno-associated virus, as gene transfer
vector, for CHF, 556

Adenosine receptor antagonists, for CHF,
481-482

Adenoviruses, as gene transfer vectors,
for CHF, 555, 557

Adhesion molecules, in CHF, 308, 313

Adolescents, HIV infection in, 992

Adrenal gland dysfunction, perioperative,
54
in cancer chemotherapy, 251-252

Adrenergic system gene polymorphisms,
CHF pharmacogenomics and,
571-573

Advanced sleep phase syndrome,
822-823

Advocacy, multicultural aspects of, 952

African American women
health facts about, 943-945
hot flashes in, 1094-1095

Age factors
in beta-blocker action, in CHF, 355
in perioperative thromboembolism
risk, 79

Agency for Health Care Policy and
Research, minority women's health
data from, 947

AIDS. *See* Human immunodeficiency virus
infection.

Airway obstruction, in cancer,
perioperative, 245-246

Alaskan native women, health facts about,
946-947

Albumin, preoperative measurement of, 24

- Alcohol consumption
cardiovascular risk and, in diabetes mellitus, 960
sensory neuropathy in, 695-698
- Alcoholic liver disease, perioperative, 213
- Aldactone. *See* Spironolactone.
- Aldosterone, CHF and, **441-457**
pathophysiologic aspects of, 443-447, 482-484
Randomized Aldactone Evaluation Study of, 442
receptor antagonists for, 442, 447-453, 482-485
significance of, 441-442
- Aldosterone receptor antagonists, for CHF, 482-485
clinical studies of, 442
indications for, 449-450
mechanisms of action of, 447-449
pathologic basis for, 443-447
regimen for, 450-451
selective, 451-453, 485
- Aldosterone synthase polymorphisms, CHF pharmacogenomics and, 573
- Alendronate
for osteoporosis, 1046, 1048, 1052-1053
perioperative, 46
- Allergy, to penicillin, perioperative prophylaxis and, 61-62
- Almotriptan, for migraine headache, 594-595
- Alpha-adrenergic agonists, for hot flashes, 1106-1107
- Alpha-adrenergic receptors, in CHF, 393
- Alpha-blockers, for pheochromocytoma, perioperative, 183-186
- Alprazolam, for psychogenic dizziness, 636
- Alternative therapies, perioperative, 48-49
- Ambulation, early, for thromboembolism prophylaxis, 83, 85
- American College of Cardiology
cardiac risk classification of, 112-116
preoperative cardiac assessment guidelines of, 119-122
- American College of Chest Physicians,
venous thromboembolism risk stratification criteria of, 82-83
- American College of Physicians,
preoperative cardiac assessment guidelines of, 122
- American Heart Association
cardiac risk classification of, 112-116
preoperative cardiac assessment guidelines of, 119-122
- American Indian women, health facts about, 946-947
- American Sleep Disorders Association,
sleep disorder classification of, 831-833
- American Surgical Association, cardiac risk classification of, 112
- Amidolytic assay, for protein C, 1240-1241
- Amiloride, for CHF, 479
- δ -Aminolevulinic acid accumulation, in porphyria, 717-718
- Amiodarone, perioperative, 42
- Amitriptyline
for meralgia paresthetica, 706
for sensory neuropathy, 697-698
- Amrinone, for CHF, 401
- Amygdalohippocampectomy, for epilepsy, 739-740
- Amyloid myopathy, 906-907
- Anaritide, for acute kidney failure, 198
- Anemia, perioperative, 229-235
evaluation of, 229-230
in cardiovascular disease, 232-233
in kidney failure, 203-204
in thalassemia, 233
pathophysiology of, 230-231
preoperative detection in, 9-11
sickle cell, 233
transfusions for, 231-235
- Anesthesia
in cancer, cardiopulmonary obstruction and, 245-246
in coronary artery disease, 130
in kidney failure, 205
in liver disease, 217
respiratory complications and, 160-161
- Aneurysm
brain, perioperative, 263-264
left ventricular, in CHF, surgery for, 529-530
- Angiography
in carotid artery stenosis, 759

- magnetic resonance, in brainstem stroke, 613
- Angioplasty**
 carotid, 760-761
 coronary, preoperative, 129-130
- Angiotensin-converting enzyme inhibitors**
 for CHF, **373-381**, 484-485
 beta-blocker interactions with, 355
 clinical trials of, 375-381
 cough in, 573
 mechanisms of action of, 376-377
 pharmacogenomics of, 570-571, 573
 prophylactic, 378-379
 treatment objectives and, 374-376
 uncertainties with, 373, 379-381
 versus digoxin, 327
 for hypertension, perioperative, 140
 for transient ischemic attack, 758
- Angiotensin II**, in CHF, 310
- Angiotensin receptor blockers**, for CHF, 381-385, 429
- Ankle**
 pain in, in tarsal tunnel syndrome, 682-685
 weakness of, in peroneal neuropathy, at fibular neck, 677-679
- Anorexia**, in congestive heart failure, 304
- Antiarrhythmic agents**, perioperative, 42-43, 145-146
- Antibiotic prophylaxis**, perioperative, **59-75**
 for endocarditis, 67-70
 for surgical site infections, 59-67
 benefits of, 61
 duration of, 62
 in cardiac surgery, 63-64
 in gastrointestinal procedures, 63-64
 in gynecologic surgery, 63-66
 in head and neck surgery, 65-66
 in neurologic surgery, 65-66
 in ophthalmic procedures, 65-66
 in orthopedic procedures, 65-67
 in penicillin allergy, 61-62
 in thoracic procedures, 65, 67
 in urologic procedures, 67
 in vascular procedures, 65, 67
 postoperative, 59-61
 principles of, 61-62
 risks of, 60-61
 vs. nonantimicrobial strategies, 60-61
- Anticoagulants**
 before colonoscopy, with existing deep venous thrombosis, **1205-1214**
 for calf deep venous thrombosis, **1157-1164**
 antagonist's perspective on, 1160-1162
 protagonist's perspective on, 1157-1160
 for cerebral venous thrombosis, 765-767
 for chronic inferior vena caval filter, **1189-1203**
 antagonist's perspective on, 1192-1201
 protagonist's perspective on, 1189-1191
 for iliofemoral deep venous thrombosis, 1166, 1168-1169
 perioperative, 44-47, 96-100
 in brain tumors, **1179-1187**
 in valvular heart disease, 149
- Anticytokines**, for CHF, **419-440**
 animal studies of, 422-428
 failure of, 431-434
 human studies of, 426, 429-434
 pathophysiology and, 421-422
- Antidepressants**
 for cataplexy, 816
 for hot flashes, 1103-1105
 for meralgia paresthetica, 706
 for sensory neuropathy, 697-698
 perioperative, 50-51
- Antidiuretic hormone**, inappropriate secretion of, perioperative, 246-247, 268-269
- Antidiuretic hormone receptor antagonists**, for CHF, 480-481
- Antiepileptic drugs**.
See also specific drugs.
 advantages of, 741
 breast milk transmission of, 731
 disadvantages of, 741
 for medically resistant partial-onset epilepsy, 738-740
 for new-onset epilepsy, 727-728
 in elderly persons, 732-735
 in mental retardation, 735-738
 noncompliance with, 740-741
 oral contraceptive interactions with, 729-730
 side effects of, 728
 teratogenesis due to, 730-731
- Antihypertensive agents**, perioperative, 43, 139-141

- Antiparkinsonian agents, perioperative, 49-50
- Antiphospholipid antibodies, testing for, 1240-1241
- Antiplatelet agents, perioperative, 44-46
- Antipsychotic agents, perioperative, 52
- Antiretroviral agents
for HIV infection, in women, 987-991, 993
perioperative, 48
- Antiseizure agents, perioperative, 50
- Antithrombin defects, testing for, 1239-1241, 1243, 1247-1248
- Anxiety, dizziness in, 634-636
- Anxiolytics, perioperative, 53
- Aortic regurgitation
heart failure in, treatment of, 396
perioperative, 148
- Aortic stenosis
heart failure in, treatment of, 396
perioperative, 147-148
- APC resistance assay, for factor V Leiden, 1240
- Apnea, sleep. *See* Sleep apnea.
- Apnea-hypopnea index, 812
- Apoptosis, of myocytes, in CHF, 308
gene therapy for, 559-560
- Aquaretic agents, for CHF, 480-485
- Arginine vasopressin receptor antagonists, for CHF, 480-481
- Arousal disorders, 824-825, 831
- Arrhythmias, cardiac
digoxin-induced, 321, 332-333
perioperative, 143-147
resynchronization for. *See* Cardiac resynchronization therapy.
- Arteriolar resistance, in CHF, 476
- Arteritis, temporal, headache in, 602-604
- Arthritis, sexual activity after, 1083
- Ascites, perioperative, 216-217
- Asian and Asian Pacific Islander women
health facts about, 945-946
hot flashes in, 1094
- Aspirin
for migraine headache, 594
perioperative, 44-45
for thromboembolism prophylaxis, 88-89
- Asthma
CHF with, beta-blockers contraindicated in, 359
drugs for, perioperative, 43-44
- Atasia without abasia, 800
- Ataxia, spinal cerebellar, gait in, 797-798
- Atenolol
for coronary artery disease, perioperative, 127
for reflex syncope, 846
- Atherosclerosis, carotid, 759-761
- Atrial fibrillation
in CHF, beta-blocker effects on, 349, 354
perioperative, 143-145
venous thromboembolism and, 98-99
- Atrial natriuretic peptide
description of, 485-486
for acute kidney failure, 198
for CHF, 476-477, 486-487
- Atrioventricular block, in CHF, beta-blockers contraindicated in, 360
- Atrioventricular node, digoxin effects on, 321
- Attention-deficit/hyperactivity disorder, Tourette's syndrome and, 773
- Auerbach/Goldman algorithm, for preoperative assessment, in coronary artery disease, 130-132
- Autoimmune disease, gender differences in, 931
- Autonomic nervous system
digoxin effects on, 319, 321-324
dysfunction of
acute and subacute, orthostatic hypotension in, 852-854
chronic, orthostatic hypotension in, 849-852
in migraine headache, 591
testing of, in orthostatic hypotension, 854-855
- Axilla, radial nerve compression at, 671-673
- Axillary node biopsy, in breast cancer, 1020-1021
- Azathioprine, for multiple sclerosis, 881

B

B lymphocytes, infiltration of, in multiple sclerosis, 869-870

Back pain, 641-660

- anatomic considerations in, 643-645
- epidemiology of, 642
- evaluation of, 641
- in osteomyelitis, 649-650
- in spinal stenosis
 - foot drop in, 656-658
 - numbness in, 652-654
- localized, 645-646
- nonradiating, conservative treatment of, 647-648
- pathophysiology of, 645-647
- physical examination in, 647
- radicular, 647
- referred, 647
- risk factors for, 642-643

Baclofen

- for spasticity, in multiple sclerosis, 885-886
- for trigeminal neuralgia, 711

Bacteremia, prophylaxis for, perioperative, 67-70

Bacterial vaginosis, in HIV infection, 976-977

Balance disorders. *See* Gait disorders.

Baroreceptors, carotid
digoxin effects on, 319, 323-324
in CHF, 476-477

Barr bodies, 926

Batista operation, for CHF, 534-539

Behavioral modification
for hot flashes, 1108-1109
for osteoporosis, 1049

Bellergal, for hot flashes, 1106

Bell's palsy, 700-703

Belmont Report, 920

Benediction posture, in ulnar neuropathy at elbow, 665

Benign paroxysmal vertigo, 623-627

Benzodiazepines, perioperative, 53
in kidney failure, 205

Beta-adrenergic activity, in CHF, 306-310
as gene transfer target, 560-561
sympathomimetics and, 392-401

Beta-blockers

for CHF, 314, 339-371

advanced, in drug combinations, 410

bradycardia management with, 363

clinical trials of, 342-348

age factors in, 355

agents studied, 342-343

BEST, 344, 346-347,

350-351, 354-355

beta-blocker differences in, 356-357

CAPRICORN, 344, 346,

348, 350-352

CARMEN, 345

CHRISTMAS, 345

CIBIS-II, 344, 346-347,

354, 356

COMET, 344, 352

COPERNICUS, 344,

346-348, 351-352,

354-356, 358

drug interactions in, 355

ethnic factors in, 355

in atrial fibrillation, 354

in diabetes mellitus, 355

MERIT-HF, 344, 346-347,

351-352, 354-356

MOCHA, 357-358

morbidity effects in,

349-350

mortality effects in, 350-352

patient types studied, 343

remaining issues in, 357-358

SENIORS, 344

severe, 354

subgroup analysis of,

353-355

symptom effects of, 348

tolerability in, 352-353

U.S. Carvedilol Trial

Program, 343-344,

346, 351-352

ventricular function effects

in, 349

versus heart failure etiology,

354

contraindications to, 359-361

dose for, 362

drug selection in, 361

hypotension management with,

362-363

in asymptomatic left ventricular

dysfunction, 359

initiation of, 361-362

mechanisms of action of, 340-342

myths concerning, 339-340

patient selection for, 358-359

pharmacogenomics of, 355,

571-573

- Beta-blockers** (*continued*)
 recent-onset, 359
 recommendations for, 358-359
 side effects of, 362-365
 stabilization with nonglycoside
 inotropic agents before, 412
 tumor necrosis factor- α levels
 and, 429
 worsening heart failure during,
 363-364
 for migraine headache, 596
 for reflex syncope, 846
 perioperative
 for arrhythmias, 145
 for cardiac disorders, 42
 for coronary artery disease,
 126-128
 for hypertension, 140
 for pheochromocytoma,
 184-185
- Biopsy**
 in breast cancer, 1005-1007
 temporal artery, in headache, 604
- Bisoprolol**
 for CHF, clinical trials of
 CIBIS-II, 344, 346-347, 354, 356
 mortality effects in, 350-351
 versus heart failure etiology, 354
 versus other beta-blockers, 356
 with atrial fibrillation, 354
 for coronary artery disease,
 perioperative, 126-127
- Bisphosphonates**, for osteoporosis, 1046,
 1048, 1052-1053
- Biventricular pacemaker**, for CHF,
 501-502
- Black cohosh**, for hot flashes, 1101-1103
- Bladder dysfunction**
 in menopause, 1030-1032
 in multiple sclerosis, 886-888
- Bleeding**
 perioperative, 235-239
 in brain tumors, 1184-1185
 in kidney failure, 203-204
 in liver disease, 216
 risk factors for, 82-83, 96-98
 risk of
 in anticoagulant therapy for calf
 deep vein thrombosis,
 1157-1158, 1162
 in bridging therapy with heparin,
 1211
 in thrombolytic therapy,
 1171-1172
- Blood gas analysis**, preoperative, 163
- Blood pressure**, control of, perioperative,
 139-141
 in kidney failure, 204
 in neurologic disease, 266-267
- Blood vessels**, aldosterone effects on,
 444-447
- BMS-193884** (endothelin receptor
 antagonist), for CHF, 468
- Bone**
 gender differences in, 926-927
 remodeling of, 1040-1041
- Bone loss**, in multiple sclerosis, 890
- Bone mass density**, in osteoporosis
 measurement of, 1041-1042, 1045
 monitoring of, 1056-1057
 parathyroid hormone effects on,
 1054-1055
 raloxifene effects on, 1051
- Bosentan**
 for CHF, 465, 467
 for kidney failure, 465
- Botulinum toxin**
 for dystonia, 776-777
 for spasticity, in multiple sclerosis, 886
- Bowel dysfunction**, in multiple sclerosis, 888
- BQ-123** (endothelin receptor antagonist),
 for CHF, 466-467, 469
- BQ-788** (endothelin receptor antagonist),
 for CHF, 466-467
- Brachial plexopathy**, 714-716
- Brachytherapy**, for breast cancer, 1022
- Bradbury-Eggleston syndrome**, orthostatic
 hypotension in, 854
- Bradyarrhythmias**, perioperative, 146
- Bradycardia**
 in CHF
 beta-blockers contraindicated in,
 360
 in beta-blocker therapy,
 management of, 363
 in neurally mediated syncope, 837, 840
 in seizures, 848
- Bradykinin receptor gene polymorphisms**,
 CHF pharmacogenomics and, 573
- Brain**
 aneurysm of, perioperative
 management in, 263-264
 gender differences in, 928-929
 injury of, hypersomnia after, 817
 lobar hemorrhage of, 764-767

- tumors of
 - perioperative management in, 264-265
 - thromboprophylaxis for, **1179-1187**
- Brain natriuretic peptide
 - description of, 485-486
 - for CHF, 410, 476-477, 486-487
 - versus dobutamine, 397
- Brainstem, infarction of, dizziness in, 611-614
- Breast cancer, **997-1028**
 - black cohosh and, 1102
 - diagnosis of, 1004-1007
 - biopsy methods for, 1006-1007
 - nonpalpable mass evaluation, 1005-1006
 - palpable mass evaluation, 1004-1005
 - multicultural considerations in, 943-947
 - risk of
 - identification of, 1013-1015
 - reduction of, 1008-1012
 - screening for, 998-1004
 - magnetic resonance imaging in, 1004
 - mammography in, 998-1003
 - self-examination in, 998
 - ultrasonography in, 1003-1004
 - sexual activity after, 1083
 - treatment of, 1016-1023
 - adjuvant systemic therapy in, 1022-1023
 - axillary surgery in, 1020-1021
 - conservative, 1016-1018
 - neoadjuvant chemotherapy in, 1018-1020
 - radiation therapy in, 1022
- Breast-feeding
 - HIV transmission in, 986-987
 - in epilepsy, 731
- Breast pain, discussion of, communication in, 1131-1132
- Breathing disorders, sleep disorders in, 809-814
 - central sleep apnea-hypopnea syndrome, 813-814
 - mixed sleep apnea, 810-812
 - obstructive sleep apnea, 809-812, 821
- Bromocriptine, for CHF, 399-400
- Bucindolol, for CHF
 - clinical trials of, BEST, 344, 346-347, 350-351, 354-355
 - pharmacogenomics of, 571-572

- Bugbane, for hot flashes, 1101-1103
- Bumetanide, for CHF, 478-479
- Bundle branch block, perioperative, 146
- Bureau of Primary Health Care's Office of Minority and Women's Health Care Policy and Research, minority women's health data from, 947
- Butalbital combination medications, for migraine headache, 594
- Butorphanol, for migraine headache, 594
- Buttock pain, in piriformis syndrome, 686-688
- Butyrophenones, perioperative, 52

C

- C-reactive protein
 - cardiovascular risk from, in diabetes mellitus, 961
 - measurement of, in temporal arteritis, 604
- C-type natriuretic peptide, 485
- Cadherins, in CHF, 313
- Calcitonin
 - for osteoporosis, 1047-1048, 1053-1054
 - perioperative, 46, 48
- Calcium
 - handling of, as gene transfer target, for CHF, 556-559
 - in digoxin action, 319-320
 - supplementation with, for osteoporosis, 1049
- Calcium channels, phosphorylation of, in CHF, 308-310
- Calf, deep venous thrombosis of
 - anticoagulants for, **1157-1164**
 - antagonist's perspective on, 1160-1162
 - protagonist's perspective on, 1157-1160
 - clinical significance of, 1161
 - epidemiology of, 1160
 - natural history of, 1158-1159
- Canalith repositioning, for benign paroxysmal vertigo, 624-627
- Cancer
 - breast. *See* Breast cancer.
 - cervical, in human papillomavirus infections, in HIV infection, 980-982

Cancer (*continued*)

- multicultural considerations in, 943-948
 - paraneoplastic syndromes in
 - acute autonomic neuropathy, 853
 - sensory neuropathy, 712-713
 - perioperative management of, **243-256**
 - cardiopulmonary considerations in, 245-246
 - chemotherapy effects in, 249-252
 - endocrine considerations in, 246-247
 - hematologic considerations in, 247-248
 - metabolic considerations in, 246-247
 - neurologic considerations in, 249
 - nutritional status and, 244
 - pain and, 244-245
 - performance status variations and, 244
 - radiation therapy effects in, 252-253
 - thromboembolism risk in, 81
- Candesartan, for CHF, 385, 429
- Candidiasis, vulvovaginal, in HIV infection, 978-979
- Canrenone, for CHF, 485
- Capsaicin, for meralgia paresthetica, 706
- Captopril, for CHF
 - pharmacogenomics of, 571
 - versus digoxin, 326
 - versus losartan, 384-385
- Carbamazepine
 - for epilepsy
 - advantages of, 741
 - breast milk transmission of, 731
 - disadvantages of, 741
 - in elderly persons, 733
 - in mental retardation, 735-738
 - in pregnancy, 729-731
 - new-onset, 728
 - side effects of, 728
 - for multiple sclerosis, 878
 - for sensory neuropathy, 697-698
 - for trigeminal neuralgia, 711
- Carbidopa-levodopa
 - for Parkinson's disease, 785-786
 - for restless legs syndrome, 820
 - perioperative, 49-50
- Cardiac arrhythmias. *See* Arrhythmias.
- Cardiac catheterization, right heart, perioperative, 141-142
- Cardiac drugs, perioperative, 42-43

Cardiac glycosides. *See also* Digoxin.
for CHF, 317-318

Cardiac index, digoxin effects on, 323

Cardiac output

- in congestive heart failure, 304
- reduced, cardiovascular risk and, in diabetes mellitus, 964

Cardiac pacing, for reflex syncope, 847

Cardiac procedures, antibiotic prophylaxis for, 63-64

Cardiac resynchronization therapy, for CHF, 501-502, **509-521**

- clinical trials of, 513-518
 - CARE-HF, 518
 - COMPANION, 517-518
 - CONAK CD, 517-518
 - MIRACLE, 515-516
 - MIRACLE ICD, 517
 - MUSTIC, 515
 - PATH-CHF, 514
- historical view of, 509-511
- mechanisms of action of, 511-512
- patient selection for, 518-519
- remodeling in, 513

CardioClasp[®], for CHF, 547

Cardiogenic shock, dopamine for, 398-399

Cardiomyopathy

- dilated, CHF in
 - beta-blocker effects on, 349
 - digoxin effects on, 323
 - surgical treatment of. *See* Surgery, for CHF.
- of overload, in CHF, 307-308
- perioperative, 142-143

Cardiovascular system. *See also* Heart.
disorders of

- headache in, 602-603
- in diabetes mellitus. *See* Diabetes mellitus, cardiovascular risk in.
- multicultural considerations in, 943-947
- gender differences in, 927-928

Cardioverter-defibrillator, implantable, perioperative management with, 146-147

Carnitine, for CHF, 494-495

Carotid artery(ies), stenosis of, 759-761

Carotid artery disease, perioperative management in

- in endarterectomy, 261-263
- in general surgery, 258-259

- Carotid baroreceptors, digoxin effects on, 319, 323-324
- Carotid sinus
hypersensitivity of, syncope in, 841-842
massage of, in syncope, 845
- Carpal tunnel syndrome, 661-664, 706-708
- Carvedilol, for CHF
clinical trials of, 343-348
age factors in, 355
dose for, 357-358
ethnic differences in, 355
in severe heart failure, 354
morbidity effects in, 350
mortality effects in, 350-352
patient selection for, 344, 346-348, 351-358
symptom effects of, 348
tolerability in, 352-353
versus heart failure etiology, 354
versus other beta-blockers, 356-357
with atrial fibrillation, 354
pharmacogenomics of, 572-573
- Catamenial seizures, 732
- Cataplexy, in narcolepsy, 814, 816
- Catecholamines, excess of, in pheochromocytoma, perioperative management of, 183-186
- Catheterization, cardiac, right heart, perioperative, 141-142
- Centers for Disease Control, minority women's health data from, 947
- Central nervous system. *See also* Brain. gender differences in, 928-929
- Central positional vertigo, 627-629
- Central sleep apnea-hypopnea syndrome, 813-814
- Cephalosporins, for postoperative infection risk reduction, 61-62, 64-65
- Cerebellar artery infarcts, dizziness in, 613-614
- Cerebellar ataxia, spinal, gait in, 797-798
- Cerebral venous thrombosis, 764-767
- Cerebrospinal fluid, drainage of, for normal pressure hydrocephalus, 797
- Cerebrovascular disease, **755-770**
acute stroke, 761-762
carotid stenosis, 759-761
cerebral venous thrombosis, 764-767
dizziness in, 762-764
epilepsy in, 732-735
headache in, 764-767
lobar hemorrhage, 764-767
minor stroke, 755-758
perioperative management in, 257-258
transient ischemic attack, 755-758
- Cervical dystonia, 775-777
- Cervical intraepithelial neoplasia, in human papillomavirus infections, in HIV infection, 980-982
- Cervicitis, in HIV infection, 979
- Cervix, human papillomavirus infections of, in HIV infection, 980-982
- Charcot-Marie-Tooth disease, 703-704, 799
- Chemotherapy, for cancer
breast
adjuvant systemic, 1022-1023
neoadjuvant, 1018-1020
perioperative management of, 249-252
- Chest pain
discussion of, communication in, 1130-1131
in herpes zoster, 698-700
- Chest physical therapy, postoperative, 168
- Chest radiography, preoperative, 28-29, 32-34, 163
- Cheyne-Stokes breathing, in sleep apnea, 813
- CHF. *See* Congestive heart failure.
- Chlorpromazine, perioperative, 52
- Chlorthalidone, for CHF, 479
- Cholecystitis, acalculous, postoperative jaundice in, 221
- Cholesterol, excess of, cardiovascular risk from, in diabetes mellitus, 958-959
- Chorea, Huntington's, 788-789
- Chromosomes, sex, in gender-specific medicine, 925-926
- Chronic fatigue syndrome, versus orthostatic intolerance, 858-859
- Chronic obstructive pulmonary disease, perioperative management of
drugs for, 43-44
respiratory complications in, 156
thromboembolism risk in, 81
- Chronotherapy, for sleep disorders, 823
- Cilostazol, perioperative, 45

- Cimicifuga racemosa* (black cohosh), for hot flashes, 1101-1103
- Circadian rhythm disorders, sleep disorders in, 822-823, 831
- Cirrhosis, perioperative, 24-25, 213-217
- Citalopram, perioperative, 51-52
- Claudication, neurogenic, in spinal stenosis, 652-654
- Clindamycin, for bacterial vaginosis, 977
- Clinical studies, historical background of, 919-922
- Clomipramine, for cataplexy, 816
- Clonazepam
for REM sleep behavior disorder, 826
for restless legs syndrome, 820
for spinal myoclonus, 778-779
- Clonidine
for hot flashes, 1106-1107
perioperative
for coronary artery disease, 128
for hypertension, 43, 140
- Clopidogrel, perioperative, 45
- Clotting assay, for protein C, 1240-1241
- Cluster headache, episodic, 592-593
- Coagulation disorders, perioperative, 235-239
in cancer, 247-248
in liver disease, 216
- Coagulation tests, preoperative, 14-17
- Cognitive dysfunction, in multiple sclerosis, 890
- Collagen
denaturation of, tumor necrosis factor- α in, 424-425
of blood vessels, aldosterone effects on, 445-446
- Colonoscopy, with existing deep venous thrombosis, anticoagulants before, **1205-1214**
- Colostomy, sexual activity after, 1083
- Communication, patient-doctor, **1115-1145**
clinical settings for, 1125-1126
components of, 1116
cue recognition in, 1117-1118
gaps in, 1115-1116
gender differences in, 1121-1123
health literacy and, 1124-1125
importance of, 1115
in informed consent, 1134-1135
in pain discussions, 1128-1132
in physical activity counseling, 1126-1128
in terminal illness, 1132-1134
modalities for, 1136
multicultural issues in, 948-951, 1123-1125
new modalities for, 1116
nonverbal, 1117
setting tone for, 1117-1118
structured interview model for, 1118-1121
tools for, 1135-1141
- Complementary medicine, multicultural issues in, 950-951
- Compression devices, pneumatic, for thromboembolism prophylaxis, 85-87
- Compressive neuropathy. *See* Entrapment and compressive neuropathy.
- Computed tomography
in epilepsy, 726
in syncope, 46
in transient ischemic attack, 757
- Conduction system
digoxin effects on, 321
disorders of
in CHF, resynchronization for.
See Cardiac resynchronization therapy.
perioperative, 143-147
- Confusional arousals, from sleep, 824
- Congestive heart failure
clinical features of, 303-304
historical description of, 303
pathophysiology of, **303-316**
architectural changes in, 304-305
fight or flight response in, 306
functional response in, 306-314
historical description of, 303
impaired pump function in, 304
kidney role in, 475-478
opposing mechanisms in, 306-308
overload in, 307-308
proliferative abnormalities in, 304-314
surgical treatment methods and, 524-527
sympathomimetic action and, 392-394
perioperative, 81, 141-143
treatment of
advanced, 410-411
adverse effects of, 313-314

- aldosterone targeting for, **441-457**
 - angiotensin-converting enzyme inhibitors for. *See* Angiotensin-converting enzyme inhibitors.
 - angiotensin receptor blockers for, 381-385, 429
 - anticytokine agents in, **419-440**
 - beta-blockers for, 314, **339-371**
 - biventricular pacing in, 411, 501-502, **509-521**
 - chronic systolic, 396, 410
 - digoxin for. *See* Digoxin.
 - electrophysiologic aids for, **509-521**
 - endothelin receptor antagonists for, **459-474**
 - for salt and water retention, **475-491**
 - gene transfer for, **553-567**
 - in bridge to transplantation, 396-398
 - in pseudosepsis syndrome, 411-412
 - metabolic modulation and optimization for, **493-507**
 - nonglycosidic inotropic agents for, **391-418**
 - objectives of, 374-376
 - old paradigm for, 304-305
 - pathophysiologic considerations in, **303-316**, 475-478, 524-527
 - pharmacogenomics of, **569-579**
 - prophylactic, 378-379
 - quality of life issues in, 411
 - refractory, 396-398, 410
 - resynchronization therapy in, 411, 501-502, **509-521**
 - severe, beta-blockers for, 354
 - surgical, **523-552**
 - versus etiology, beta-blockers in, 354
- Consciousness, sudden loss of. *See* Syncope.
- Constipation, in multiple sclerosis, 888
- Consultation, preoperative, **1-6**
- benefits of, 5
 - comanagement in, 5
 - compliance with recommendations, 3-4
 - primary reason for, 2
 - principles of, 1-2
 - results of, 2-3
- Continuous positive airway pressure, for obstructive sleep apnea-hypopnea syndrome, 812
- Contraception
- in HIV infection, 991
 - oral. *See* Oral contraceptives.
- Conversion disorder, dizziness in, 620-621
- Convulsive syncope, 843-844
- Coproporphria, 718-719
- Core biopsy, in breast cancer, 1007
- Coronary angioplasty, preoperative, 129-130
- Coronary artery bypass grafting for CHF, 527-529
- preoperative, 128-129
- Coronary artery disease
- perioperative management in, **111-136**
 - algorithm for, 130-132
 - anesthetic considerations in, 130
 - clinical risk assessment in, 119-122
 - echocardiography in, 122-123, 125
 - electrocardiography in, 118, 125-126
 - goals of, 112
 - history in, 116-118
 - in kidney failure, 200-202
 - myocardial perfusion imaging in, 124-125
 - noninvasive tests for, 122-126
 - percutaneous interventions in, 129-130
 - pharmacologic, 126-128
 - physical examination in, 118
 - preoperative bypass grafting in, 128-129
 - previous test results for, 118
 - pulmonary artery catheter information in, 130
 - risk indices for, 112-116
 - stress testing in, 123-124
 - risk of, in diabetes mellitus. *See* Diabetes mellitus, cardiovascular risk in.
- Corticosteroids
- for Bell's palsy, 702
 - for carpal tunnel syndrome, 664
 - myopathies due to, 903-904
 - perioperative, 54, 186-189
 - for hyperthyroidism, 183
- Costs, of thrombolytic therapy, 1171
- Cough, angiotensin-converting enzyme inhibitor-induced, 573
- Cough syncope, 842-843

Counseling

- on physical activity, communication techniques for, 1126-1128
- on terminal illness, communication techniques for, 1132-1134
- preconception, in HIV infection, 992

Craniotomy, antibiotic prophylaxis for, 65-66

Creatine kinase, excess of, myopathy in, 899-900

Cryoprecipitate, for bleeding, in kidney failure, 203-204

Cuban American women, health facts about, 945

Cubital tunnel syndrome, 664-668

Cultural considerations. *See* Multicultural considerations.

Cyclophosphamide, for multiple sclerosis, 881

CYP11B2, for aldosterone synthase, polymorphisms of, 572-573

CYP2D6, in beta-blocker metabolism, polymorphisms of, 572-573

Cytochrome P-450 system, gender differences in, 932-933

Cytokines, inhibitors of, in CHF, 419-440

Cytoskeleton, proliferative signaling effects on, in CHF, 310-313

D

Dalteparin, for thromboembolism prophylaxis, 90-93, 100-101

Darusentan, for CHF, 467-469

DDAVP (desmopressin)

- for bladder dysfunction, 888
- for bleeding, in kidney failure, 203-204

Death and dying, counseling on, communication techniques for, 1132-1134

Debates

- on anticoagulants for deep vein thrombosis, 1157-1164
- on comprehensive hypercoagulable state testing in deep vein thrombosis, 1237-1250
- on echocardiography in acute pulmonary embolism, 1251-1262
- on heparin-induced thrombocytopenia diagnosis, 1215-1224

on oral contraceptives in factor V Liden heterozygosity, 1225-1236

on precolonoscopy bridging therapy in deep venous thrombosis, 1205-1214

on thrombolytic therapy for iliofemoral thrombosis in young patients, 1165-1177

on thromboprophylaxis for brain tumor surgery, 1179-1187

for inferior vena caval filters, 1189-1203

Decision-making, patient, communication about, 1134-1135, 1140-1141

Deep brain stimulation, for essential tremor, 783-784

Deep venous thrombosis. *See* Venous thromboembolism.

Dehydroepiandrosterone, for sexual dysfunction, in females, 1084-1085

Delayed sleep phase syndrome, 822

Delirium, postoperative in elderly persons, 277-278 in neurologic disease, 267-268

Dementia

in diffuse Lewy body disease, 774-775 perioperative, 259-260

Demyelination, in multiple sclerosis, 869-870

Dendroaspis natriuretic peptide, 485

Dental procedures

endocarditis prophylaxis in, 69 long-term oral anticoagulation management in, 97

Depression

in multiple sclerosis, 889-890 in women, 1065-1076 epidemiology of, 1065-1066 estrogen and, 1066-1067 in climacteric, 1070-1072 in menopause, 1070-1072 neurotransmitters and, 1069-1070 pathogenesis of, 1065-1066 pharmacoendocrinologic interventions for, 1067-1069 postpartum, 1068 selective serotonin reuptake inhibitors for, 1070, 1072-1073

Dermatomyositis, 904-906

- Desirudin, for thromboembolism prophylaxis, 93
- Desmopressin
for bladder dysfunction, 888
for bleeding, in kidney failure, 203-204
- Developmental disability
epilepsy in, 735-738
sexuality in, 1084
- Dexamethasone, for multiple sclerosis, 873
- Dextroamphetamine, for narcolepsy, 816
- Diabetes mellitus
cardiovascular risk in, in women, **955-969**
alcohol consumption, 960
dyslipidemia, 958-959
endothelial dysfunction, 961-962
fibrinolysis, 960-961
hypertension, 959
impaired exercise tolerance, 962-964
in prediabetic state, 965
inflammatory biomarkers, 961
obesity, 960
reduced physical activity, 962
smoking, 959
versus men, 956-958
in CHF, beta-blockers contraindicated in, 361
meralgia paresthetica in, 679-682
multicultural considerations in, 944-946
orthostatic hypotension in, 849-852
perioperative management in, 44, 175-181
glucose control in, 22-24, 44
hyperglycemia significance in, 176-177
in cancer chemotherapy, 251
intraoperative, 178-180
metabolic changes in, 176
postoperative, 180-181
preoperative evaluation, 177-178
sensory neuropathy in, 695-698
- Dialysis, for kidney failure
acute, 198-199
end-stage, 202-203
sexual activity and, 1083
- Diarrhea, in beta-blocker therapy, 364
- Dichloralphenazone, for migraine headache, 594
- Dietary supplements, for hot flashes, 1095-1096
- Diffuse Lewy body disease, 774-775
- Digital mammography, 1003
- Digital neuropathy (Morton's neuroma), 688-690
- Digoxin, for CHF, **317-337**
acute therapeutic effects of, 321, 323-324
autonomic effects of, 319, 321-324
beta-blockers with, 355, 364-365
clinical trials of, 324-328
dose of, 330, 332
drug interactions with, 332
electrophysiologic effects of, 321
hemodynamic effects of, 321, 323
history of, 317-318
mechanisms of action of, 318-322
mortality rate effects of, 328-331
perioperative, 42
pharmacology of, 330, 332-333
positive inotropic effect of, 319-320
recommendations for, 333-334
sodium/potassium ATPase effects of, 318-319
synergistic activity of, 323
toxicity of, 321, 332-333
- Dilated cardiomyopathy. *See under* Cardiomyopathy.
- Diltiazem, drug interactions with, beta-blockers, 359-360
- Diplopia, in multiple sclerosis, 877-878
- Dipyridamole, perioperative, 45
- Disk herniation, neck pain in, 654-656
- Disuse equilibrium, 618-619
- Diuretics, for CHF, 478-479
- Dix-Hallpike test, for benign paroxysmal vertigo, 625-626
- Dizziness, **607-639**
acute vertigo, 607-615
in brainstem infarct, 611-614
in inner ear infections, 607-611
in vestibular neuritis, 607-611, 798
in vestibular schwannoma, 614-615
chronic, 615-623
in cerebrovascular disease, 762-764
in disuse dysequilibrium, 618-619
in leukoaraiosis, 619-620
in progressive supranuclear palsy, 795-796
in vestibular hypofunction, 615-618
in whiplash injury, 650-652

- Dizziness, (continued)**
 medication-induced, 621-623
 psychogenic, 620-621
 spells of, 623-637
 in benign paroxysmal positional vertigo, 623-627
 in central positional vertigo, 627-629
 in hydrops, 636-637
 in Meniere's disease, 636-637
 in migraine, 634
 in orthostatic hypotension, 632-633
 in perilymphatic fistula, 629-630
 in superior canal dehiscence, 630-632
 in transient ischemic attacks, 633
 psychogenic, 634-636
- Do-not-resuscitate status, in elderly persons, perioperative management and, 285**
- Dobutamine, for CHF, 325, 394-398, 401, 406**
 advanced, 410-411
 costs of, 411
 hemodynamic effects of, 395-396
 indications for, 395-399
 mechanism of action of, 394-395
 monitoring of, 397
 versus milrinone, 406
 versus newer agents, 397-398
 versus nitroprusside, 397
- Dobutamine stress echocardiography, preoperative**
 in coronary artery disease, 125
 in kidney failure, 201
- Donepezil, for diffuse Lewy body disease, 774**
- Dong quai, for hot flashes, 1105**
- Dopamine**
 for acute kidney failure, 198
 for CHF, 398-399, 401
 in myocardial infarction, 409
 receptors for, 393-394
 versus dobutamine, 395
 for pseudosepsis syndrome, 411-412
 for septic shock, 410
- Dopamine β -hydroxylase deficiency, orthostatic hypotension in, 854**
- Dopexamine, for CHF, 399**
- Dor procedure, for CHF, 530-534**
- Dorsal root ganglia, neuropathy of, 713**
- Drop attacks, versus syncope, 856**
- Droperidol, perioperative, 52**
- Drosiprenone, for CHF, 453**
- Drug(s)**
 dizziness due to, 621-623
 metabolism of, gender differences in, 932-933
 orthostatic hypotension due to, 855
 perioperative
 adverse reactions to
 in kidney failure, 204-205
 in liver disease, 217
 usual, **41-57**
 anticoagulants, 44-47
 antihypertensive, 43
 antiplatelet agents, 44-46
 cardiac, 42-43
 endocrine, 53-55
 HIV agents, 48
 in diabetes mellitus, 44
 neurologic, 49-50
 osteoporosis agents, 46, 48
 psychiatric, 50-53
 pulmonary, 43-44
 rheumatologic, 55
 sexual activity effects of, 1083
 testing of, clinical studies of, 921-922
- Dual-energy x-ray absorptiometry, in bone mass density measurement, 1042, 1045**
- Ductal hyperplasia, atypical, cancer development from, 1013**
- Ductal lavage, for breast cancer risk evaluation, 1015**
- Dysferlinopathy, 901-902**
- Dyslipidemia, cardiovascular risk in, in diabetes mellitus, 958-959**
- Dyspareunia, 1081**
- Dyspnea**
 in CHF, metabolic modulators for, 493-507
 paroxysmal nocturnal, in sleep apnea, 810-812
- Dyssomnias, 831**
- Dystonia, 775-777**
 in multiple sclerosis, 878
 nocturnal paroxysmal, 826
- Dystrophinopathy, 901-902**
- E**
- Ear**
 canalith repositioning in, for benign paroxysmal vertigo, 624-627
 inner, infections of, 607-611

- Meniere's disease of, 636-637
perilymphatic fistula of, 629-630
superior canal dehiscence in, 630-632
- Echinacea, perioperative, 48
- Echocardiography
in acute pulmonary embolism,
1251-1262
antagonist's perspective on,
1256-1259
protagonist's perspective on,
1251-1256
in transient ischemic attack, 758
preoperative
in coronary artery disease,
122-123, 125
in kidney failure, 200-202
in nonischemic heart disease, 139
- Education, patient, on women's health,
resources for, 1138-1140
- Ejection fraction, in CHF, beta-blocker
effects on, 349
- Elastic stockings, for thromboembolism
prophylaxis, 85
- Elbow, ulnar neuropathy at, 664-668,
708-709
- Elderly persons
disuse equilibrium in, 618-619
epilepsy in, 732-735
fear of falling in, 618-619
gait in, 800-801
headache in, 602-604
perioperative management of, 273-289
age-related physiologic
considerations in, 275-277
complication prediction and
prevention in, 276-281
demographics and, 274-275
do-not-resuscitate status and, 285
generalist role in, 286
in delirium, 277-279
in immobility, 279-280
in incontinence, 281
in infections, 281
in malnutrition, 280-281
surgical outcomes in, 281-284
sexuality in, 1084
- Ejectal status epilepticus of sleep,
826-827
- Electro-oculography, in sleep disorders,
806-807
- Electroacupuncture, for hot flashes, 1108
- Electrocardiography
gender differences in, 927-928
in sleep disorders, 806-807
in syncope, 845
preoperative, 26, 28, 30-31
in coronary artery disease, 118,
125-126
in kidney failure, 201-202
in nonischemic heart disease, 139
- Electrodiagnosis
of carpal tunnel syndrome, 663-664
of interdigital neuropathy, 689
of meralgia paresthetica, 682
of peroneal neuropathy, at fibular
neck, 678-679
of piriformis syndrome, 687
of radial neuropathy, at spiral
groove, 672-673
of suprascapular neuropathy, 676
of tarsal tunnel syndrome, 684-685
of ulnar neuropathy
at elbow, 668
at wrist, 669-670
- Electroencephalography
in epilepsy, 726
in sleep disorders, 806-807
in syncope, 46
- Electrolytes, measurement of, preoperative,
17-19
- Electromyography
in carpal tunnel syndrome, 663-664,
707-708
in meralgia paresthetica, 682
in peroneal neuropathy, at fibular
neck, 679
in radial neuropathy, at spiral groove,
672-673
in sleep disorders, 806-807
in spinal myoclonus, 778-779
in suprascapular neuropathy, 676
in tarsal tunnel syndrome, 684-685
in ulnar neuropathy, at wrist, 670
- Electrophysiologic aids, for CHF. *See*
Cardiac resynchronization therapy.
- Electrophysiologic effects, of digoxin, 321
- Eletriptan, for migraine headache,
595-596
- Embolism
pulmonary. *See* Pulmonary embolism.
venous. *See* Venous
thromboembolism.
- Enalapril, for CHF
clinical trials of, 345
pharmacogenomics of, 570
tumor necrosis factor- α levels and, 429
- Encephalopathy, hepatic, perioperative, 216

- Enderectomy, carotid, 759-761
perioperative management in, 261-263
- Endocarditis, prophylaxis for, perioperative, 67-70
- Endocrine system. *See also specific glands and hormones.*
dysfunction of, perioperative, **175-192**
diabetes mellitus. *See Diabetes mellitus.*
in cancer, 246-247
- Endothelial dysfunction, cardiovascular risk from, in diabetes mellitus, 961-962
- Endothelin
actions of, 459-463
expression of, 459
in CHF, activation of, 460-463
in kidney function, 463
in myocardial function, 463
structures of, 459
- Endothelin receptor antagonists, **459-474**
endothelin biology and, 459-463
for CHF
mixed, 465, 469
myocardial remodeling and, 468-469
selective, 465-466, 468-469
for kidney failure, 465
- Endothelium, aldosterone effects on, 442-444
- Enoxaparin
for thromboembolism prophylaxis, 90-93, 101
perioperative, in brain tumors, 1181, 1185
- Enoximone, for CHF, 403, 405-407
- Entacapone, for Parkinson's disease, 785-786
- Entrapment and compressive neuropathy, **661-694**
interdigital (Morton's neuroma), 688-690
lateral femoral cutaneous (meralgia paresthetica), 679-682, 704-706
median (carpal tunnel syndrome), 661-664, 706-708
peroneal, at fibular neck, 677-679
proximal sciatic (piriformis syndrome), 686-688
radial, at spiral groove, 670-673, 719-720
suprascapular, 673-677
tibial (tarsal tunnel syndrome), 682-685
- ulnar
at elbow, 664-668, 708-709
at wrist, 668-670
- Enzyme-linked immunosorbent assay, in heparin-induced thrombocytopenia, 1217-1218, 1221
- Ephedra, perioperative, 49
- Epidural catheters, heparin-induced complications of, 92-93
- Epilepsy, **723-744**
breast-feeding during, 731
causes of
age-specific, 726-727
in elderly persons, 733-734
differential diagnosis of, 725
in developmental disability, 735-738
in elderly persons, 732-735
in mental retardation, 729-732, 735-738
in women of child-bearing age, 729-732
intractable, pitfalls in, 740-742
medically resistant partial-onset, 738-740
new-onset, 723-729
counseling on, 729
history in, 723-724
initial evaluation of, 724-727
laboratory evaluation of, 727
treatment of, 727-728
perioperative, 260-261
pregnancy in, 729-732
refractory, 848
severe, 735-738
sleep-related, 826-827
versus pseudoseizures, 742
- Epinephrine, for CHF, 400-401, 409
- Episodic cluster headache, 592-593
- Eplerenone, for CHF, 444, 451-453, 485
- Epworth Sleepiness Scale, 805-806
- Erythrocyte sedimentation test, in temporal arteritis, 603-604
- Erythropoietic porphyria, 719
- Essential tremor, 782-785
- Estrogen(s)
cardiovascular effects of, 928
central nervous system effects of, 929, 1066-1067
deficiency of
hot flashes in, 1092-1093
osteoporosis in, 1040

- for depression, in menopause, 1067-1072
- for hot flashes, alternatives to.
See Hot flashes, treatment of.
- for osteoporosis, 1046, 1048-1049
- for sexual dysfunction, 1087
- for urogenital complaints
- incontinence, 1031-1032
 - vulvovaginal, 1030
- Women's Health Initiative report on, 1032-1034
- immune system effects of, 930-931
- oral contraceptives containing, in factor V Leiden heterozygosity, **1225-1236**
- pain response and, 930
 - perioperative use of, 46, 54-55
- Estrogen receptors, phytoestrogen action on, 1097-1098
- Etanercept, for CHF, 430-431
- Ethacrynic acid, for CHF, 478-479
- Ethical issues
- in clinical research, 919-921
 - in preoperative medical consultation, 1-2
- Ethnic factors, in CHF drug treatment.
See Pharmacogenomics, of CHF.
- Ethnicity. See Multicultural considerations.
- Ethosuximide, for epilepsy, 728
- Evening primrose oil, for hot flashes, 1105
- Evoked potentials, in multiple sclerosis, 873
- Excisional biopsy, in breast cancer, 1007
- Exercise
- counseling on, communication techniques for, 1126-1128
 - for disuse equilibrium, 618-619
 - for hot flashes, 1109
 - for vestibular nerve hypofunction, 616-618
 - reduced, cardiovascular risk from, in diabetes mellitus, 962
 - tolerance of, cardiovascular risk and, in diabetes mellitus, 962-964
- Exercise capacity, improvement of, in CHF, metabolic modulators for, 493-507
- Exercise stress testing, preoperative
- in coronary artery disease, 123-124
 - in kidney failure, 200-202
- Eye, surgery on, antibiotic prophylaxis for, 65-66
- F**
- Face
- Bell's palsy of, 700-703
 - masked, in Parkinson's disease, 781-782
 - pain in, in trigeminal neuralgia, 711-712
- Facial neuropathy, in Bell's palsy, 700-703
- Factor V Leiden
- suitability of estrogen-containing oral contraceptives in, **1225-1236**
 - antagonist's perspective on, 1231-1235
 - protagonist's perspective on, 1225-1231
 - testing for, 1239-1240, 1243-1244
- Falls
- fear of
 - dizziness in, 618-619
 - gait disorders in, 799-800
 - in leukoaraiosis, 620
 - in narcolepsy, 814
 - in progressive supranuclear palsy, 795-796
 - prevention of, for fracture prevention, 1049
- Famciclovir
- for Bell's palsy, 702
 - for herpes zoster, 699
- Fat redistribution syndromes, in antiretroviral therapy, 990-991
- Fatigue
- in multiple sclerosis, 889
 - in orthostatic intolerance, 857-859
 - management of, in CHF, metabolic modulators for, 493-507
- Feldman classification, of inotropic agents, 392
- Female sexuality, **1077-1090**
- aging effects on, 1084
 - alternative forms of, 1086
 - assessment of, 1086-1087
 - determining factors of, 1077-1078
 - illness and, 1081-1084
 - management of, 1087
 - sexual disorders and, 1080-1081
 - sexual response cycle and, 1079-1080
 - testosterone and, 1084-1086
- Feminism, historical background of, 917-919
- Femoral cutaneous neuropathy, lateral (meralgia paresthetica), 679-682, 704-706

- Femoral vein, thrombosis in,
hypercoagulable state testing in,
1237-1250
antagonist's perspective on, 1242-1248
protagonist's perspective on,
1237-1242
- Fenoldopam, for CHF, 399-400
- Fertility, phytoestrogen effects on, 1099
- Fibrinogen, cardiovascular risk from, in
diabetes mellitus, 961
- Fibrinolysis, impaired
cardiovascular risk from, in diabetes
mellitus, 960-961
testing for, 1238, 1243-1244
- Fibroblasts, of blood vessels, aldosterone
effects on, 445-446
- Fibrosis, of cardiovascular structures,
aldosterone effects on, 447
- Fight or flight response, in CHF, 306
- Filters, inferior vena caval. *See* Vena cava,
inferior, filters for.
- Fine-needle aspiration biopsy, in breast
cancer, 1005-1007
- Finger drop, in radial neuropathy, 670-673
- Fistula, perilymphatic, 629-630
- Flosequinan, for CHF, 403
- Flow cytometry, in heparin-induced
thrombocytopenia, 1218
- Fludrocortisone
for orthostatic hypotension, 632,
855-856
for reflex syncope, 846
- Fluid retention, in CHF. *See* Kidney,
dysfunction/failure of, in CHF.
- Fluid status, postoperative respiratory
complications and, 157
- Fluid therapy, perioperative
for acute kidney failure prevention,
197
for chronic kidney failure, 202-203
- Fluoxetine
for cataplexy, 816
for depression, 1072-1073
for hot flashes, 1104
perioperative, 51-52
- Fluphenazine, perioperative, 52
- Flurazepam, for insomnia, 819
- Flushing, vasomotor. *See* Hot flashes.
- Fluvoxamine, perioperative, 51-52
- Fondaparinux, for thromboembolism
prophylaxis, 90-93
- Food and Drug Administration, hormone
therapy labeling requirements of, 1033
- Foot
numbness of, in tarsal tunnel
syndrome, 682-685
sensory neuropathy of, 695-698, 799
- Foot drop, in peroneal neuropathy, at
fibular neck, 677-679
- Foot pain
in interdigital neuropathy, 688-690
in sensory neuropathy, 695-698
in tarsal tunnel syndrome, 682-685
in thallium poisoning, 713-714
- Foxglove plant, 317. *See also* Digoxin.
- FR 139317 (endothelin receptor
antagonist), for CHF, 469
- Fractures, in osteoporosis
epidemiology of, 1039-1040
prevention of. *See* Osteoporosis,
treatment of.
risk factors for, 1043
- Froment's paper sign, in ulnar neuropathy
at elbow, 665-666
- Frovatriptan, for migraine headache,
594-596
- Functional signaling, in CHF, 308-310,
312
- Furosemide
for acute kidney failure, 198
for CHF, 478-479
-
- G**
- Gabapentin
breast milk transmission of, 731
for epilepsy, 741
for hot flashes, 1107-1108
for sensory neuropathy, 697-698
for trigeminal neuralgia, 712
- Gail breast cancer risk assessment tool,
1013-1014
- Gait disorders, **793-801**
classification of, 793
diagnosis of, 794
in ataxia without abasia, 800
in ataxia, 797-798
in elderly persons, 800-801
in motor neuropathy, 799
in multiple sclerosis, 884-885

- in normal pressure hydrocephalus, 796-797
 - in orthostatic tremor, 800-801
 - in Parkinson's disease, 794-795
 - in progressive supranuclear palsy, 795-796
 - in pseudoagoraphobia, 800
 - in psychiatric disorders, 799-800
 - in sensory neuropathy, 799
 - in vestibular disease, 798
 - pathophysiology of, 793-794
 - Gamma-hydroxybutyrate, for cataplexy, 816
 - Garlic, perioperative, 48
 - Gastrointestinal system, procedures on, antibiotic prophylaxis for, 63-64
 - Gender differences
 - in anticytokine therapy, for CHF, 433
 - in autoimmune disease, 931
 - in bone architecture and metabolism, 926-927
 - in brain, 928-929
 - in cardiovascular disease risk, in diabetes mellitus, 956-958
 - in cardiovascular system, 927-928
 - in cytochrome P-450 system, 932-933
 - in immune system, 930-931
 - in pain perception, 1130
 - in pain response, 929-930
 - in patient-doctor communication, 1121-1123
 - in pulmonary function, 931-932
 - in smoking effects, 931-932
 - Gender-specific medicine, 917-937
 - clinical research and, 919-922
 - current status of, 922-923
 - future of, 933-934
 - historical background of, 918-919
 - male-female differences in, 925-933
 - bone, 926-927
 - brain, 928-929
 - cardiovascular system, 927-928
 - cytochrome P-450 system, 932-933
 - immune system, 930-931
 - pain response, 929-930
 - pulmonary system, 931-932
 - sex chromosomes, 925-926
 - public policy on, 924-925
 - questions about, 923-924
 - Gene polymorphisms, in CHF, impact on drug treatment. *See* Pharmacogenomics, of CHF.
 - Gene therapy, for myopathies, 902
 - Gene transfer, for CHF, 553-567
 - delivery method for, 556
 - targets for
 - apoptosis, 559-560
 - beta-adrenergic signaling pathway, 560-561
 - calcium handling, 556-559
 - future of, 562
 - potassium channels, 561-562
 - vectors for, 554-556
 - General surgery, thromboembolism prophylaxis for, 94
 - Genital ulcer disease, in HIV infection, 982-983
 - Genital warts, in HIV infection, 982
 - Ginkgo biloba, perioperative, 48
 - Ginseng
 - for hot flashes, 1105
 - perioperative, 49
 - Glatiramer acetate, for multiple sclerosis, 880
 - Gliosis, in multiple sclerosis, 869
 - Glomerular filtration rate, in CHF, 476-477
 - Glossopharyngeal neuralgia, syncope in, 843
 - Glucocorticoids. *See* Corticosteroids.
 - Glucose
 - perioperative control of, 176-181
 - for infection risk reduction, 60
 - in kidney failure, 205-206
 - preoperative measurement of, 22-24
 - Glycosides, cardiac, 317-318. *See also* Digoxin.
 - Goldman index, of cardiac risk, 113-116
 - Goldman's "Ten Commandments" of consultation, 2
 - Granulocytosis, in cancer, perioperative, 248
 - Guillain-Barré syndrome, 709-711
 - Günther's disease, 719
 - Gynecologic surgery, antibiotic prophylaxis for, 63-66
- ## H
- Hallucinations
 - in diffuse Lewy body disease, 774-775
 - in Parkinson's disease, 785-786
 - Haloperidol, perioperative, 52

- Halothane hepatitis, 217
- Hand, weakness of, in ulnar neuropathy
at elbow, 664-668, 708-709
at wrist, 668-670
- Hawaiian women, health facts about, 946
- Head and neck surgery, antibiotic
prophylaxis for, 65-66
- Headache, **589-606**
chronic daily, 599-602
episodic cluster, 592-593
in cerebrovascular disease, 764-767
in elderly persons, 602-604
in temporal arteritis, 602-604
in whiplash injury, 650-652
migraine
dizziness in, 634
features of, 592-593
prevention of, 597-599
rebound headache in, 599-602
versus stress headache, 591,
593-594, 596-597
without aura, versus sinus
headache, 589-591
primary, 592-593
sleep-related, 826
stress, versus migraine, 591, 593-594,
596-597
tension-type, 592-593
- Healing, postoperative, hyperglycemia
effects on, 176-177
- Health literacy, patient-doctor
communication and, 1124-1125
- Heart
age-related changes in, 275-276
defects of, perioperative antibiotic
prophylaxis for, 67-70
gender differences in, 927-928
ischemic disease of. *See* Coronary
artery disease.
transplantation of
bridge to, dobutamine for,
396-398
in CHF, 528-529
- Heart block
in CHF, beta-blockers
contraindicated in, 360
perioperative, 146
- Heart disease
perioperative management in
anemia with, 232-233
chemotherapy-induced, 250
in cancer, 245-246
nonischemic, **137-152**
arrhythmias, 143-147
conduction disorders,
143-147
congestive heart failure,
141-143
hypertension, 139-141
preoperative assessment in,
137-139
valvular, 147-149
radiation-induced, 253
preoperative detection of, 28-29,
32-34
in kidney failure, 200-202
- Heart failure, congestive. *See* Congestive
heart failure.
- Heme, for porphyria, 719
- Hemodynamics, digoxin effects on, 321, 323
- Hemoglobin, preoperative measurement of,
9-11, 230
- Hemophilia, perioperative, 237-238
- Heparin
for thromboembolism prophylaxis
adjusted dose unfractionated, 93
for bridging therapy,
precolonoscopy, 1207-1212
in neurologic disease, 265-266
low dose unfractionated, 87-88
low molecular weight, 90-96, 98,
100-101, 265-266
perioperative, in brain tumors,
1180-1182, 1184-1185
thrombocytopenia due to. *See*
Thrombocytopenia, heparin-
induced.
with inferior vena caval filter,
1194-1196
- Hepatectomy, perioperative management
in, 218-219
- Hepatitis, perioperative, 212-213
- Herbal remedies
for hot flashes, 1105-1106
perioperative, 48-49
- Hereditary motor and sensory neuropathy,
703-704, 799
- Hereditary neuropathy with liability to
pressure palsy, 708, 716
- Herpes simplex virus infections, genital, in
HIV infection, 982-983
- Herpes zoster, 698-700
Ramsay Hunt syndrome in, dizziness
in, 609, 611
- Hip arthroplasty, thromboembolism
prophylaxis for, 94-95

- Hip fractures, in osteoporosis**
epidemiology of, 1039-1040
prevention of. *See* Osteoporosis, treatment of.
risk factors for, 1043
- Hippocampus, atrophy of, epilepsy in,** 738-740
- Hirudin, for thromboembolism prophylaxis,** 93
- HIV infection. *See* Human immunodeficiency virus infection.**
- Homocysteine, increased, testing for,** 1239-1241
- Hormone(s). *See also* specific hormones, eg**
Estrogen(s); Oral contraceptives, for osteoporosis, 1046, 1048-1059
for urogenital complaints
incontinence, 1031-1032
vulvovaginal, 1030
Women's Health Initiative report on, 1032-1034
perioperative, 53-55
- Hot flashes, 1091-1113**
ethnic differences in, 1093-1095
measurement of, 1096
pathophysiology of, 1092-1093
treatment of
acupuncture in, 1108
alpha-adrenergic agonists in, 1106-1107
antidepressants in, 1103-1105
behavioral therapies in, 1108-1109
black cohosh in, 1101-1103
dietary supplements in, 1095-1096
exercise in, 1108-1109
gabapentin in, 1107-1108
herbal, 1105-1106
hormone therapy in, 1067-1068
phytoestrogens in
characteristics of, 1096-1097
detrimental effects of, 1098-1100
efficacy of, 1100
mechanism of action of, 1097-1098
placebo effect in, 1096
selective serotonin reuptake inhibitors in, 1072
veralipride in, 1106
vitamin E in, 1108
- Human immunodeficiency virus infection**
drugs for, perioperative, 48
in women, **971-995**
acute retroviral syndrome in, 974-975
AIDS-defining conditions in, 973-974
asymptomatic period of, 975
bacterial vaginosis in, 976-977
cervicitis in, 979
clinical manifestations of, 974-983
detection of, 972-974
epidemiology of, 972
genital ulcer disease in, 982-983
human papillomavirus infections in, 980-982
information sources for, 971-972
pelvic inflammatory disease in, 979
postexposure prophylaxis for, 993
prevention of, 992-994
reproduction issues in, 991-992
sexually transmitted diseases with, 975
transmission of, 983-987
treatment of, 987-991
Trichomonas vaginitis in, 977-978
vulvovaginal candidiasis in, 978-979
- Human leukocyte antigens**
in multiple sclerosis, 867
in narcolepsy, 814-815
- Human papillomavirus infections, in HIV infection,** 980-982
- Huntington's disease,** 788-789
- Hydralazine, for CHF, pharmacogenomics of,** 570-571
- Hydrocephalus, normal pressure, gait in,** 796-797
- Hydrochlorothiazide, for CHF,** 479
- Hydrocortisone, perioperative,** 54
- Hydrops, dizziness in,** 636-637
- Hyoscyamine, for bladder dysfunction, in multiple sclerosis,** 887
- Hyperactivity, in Tourette's syndrome,** 771-773
- Hypercalcemia, in cancer, perioperative,** 247
- Hypercholesterolemia, cardiovascular risk from, in diabetes mellitus,** 958-959
- Hypercoagulability. *See* Thrombophilia.**

- Hyperglycemia**
in beta-blocker therapy, 364
perioperative, consequences of, 176-177
- Hypericum perforatum* (St. John's wort), for hot flashes, 1105
- Hyperkalemia**
in spironolactone therapy, for CHF, 450-451
perioperative, in kidney failure, 202-203
- Hyperperfusion syndrome**, in carotid endarterectomy, 263
- Hypersomnias**, 814-817
idiopathic, 816-817
narcolepsy, 814-816
post-traumatic, 817
- Hypertension**
ACE inhibitors for, 378-379
angiotensin receptor blockers for, 383-384
cardiovascular risk from, in diabetes mellitus, 959
in stroke, 758
perioperative, 43, 139-141
in kidney failure, 204
in neurologic disease, 266-267
in pheochromocytoma, 183-186
- Hyperthyroidism**, perioperative, 53, 182-183
- Hypertrophic obstructive cardiomyopathy**, perioperative, 142-143
- Hypoglycemia**, postoperative, in diabetes mellitus, 176
- Hypoglycemic agents**, for diabetes mellitus, perioperative, 44, 178-179
- Hypokalemic periodic paralysis**, 900-901
- Hyponatremia**, perioperative
in cancer, 246-247
in neurologic disorders, 268-269
- Hypopnea**
with central sleep apnea, 813-814
with obstructive sleep apnea, 810-812
- Hypotension**
in CHF
beta-blockers contraindicated in, 360
dopamine for, 398
in beta-blocker therapy, 362-363
orthostatic. *See* Orthostatic hypotension.
perioperative
in kidney failure, 204
in pheochromocytoma, 184
- Hypothalamic-pituitary-adrenal axis**
radiation therapy effects on, 253
surgical stress effects on, 186-189
- Hypothyroidism**, perioperative, 53, 181-182
- Hypovolemia**, idiopathic, 858
- Hysterectomy**
antibiotic prophylaxis for, 63-66
sexual activity after, 1083
-
- I**
- Ibopamine**, for CHF, 400
- Ibuprofen**, for migraine headache, 594
- Idiopathic hyper-creatine kinase-emia**, myopathy in, 899-900
- Ileostomy**, sexual activity after, 1083
- Iliofemoral deep venous thrombosis**, in oral contraceptive use, thrombolytic therapy for, **1165-1177**
antagonist's perspective on, 1169-1174
protonist's perspective on, 1165-1169
- Imipramine**, for cataplexy, 816
- Immobilization**
perioperative thromboembolism risk in, 81-82
postoperative, in elderly persons, 278-279
- Immune system**
gender differences in, 930-931
postoperative respiratory complications and, 157
- Immunoglobulin**, intravenous, for multiple sclerosis, 881
- Implantable cardioverter-defibrillator**, perioperative management with, 146-147
- Imprinting**, women's health and, 925
- Incontinence**
postoperative, in elderly persons, 281
urinary, in menopause, 1031-1032
with intercourse, 1082
- Infections**
inner ear, dizziness in, 607-611
perioperative
in elderly persons, 281
prevention of. *See* Antibiotic prophylaxis.

Inferior vena caval filters. *See* Vena cava, inferior, filters for.

Inflammatory biomarkers, cardiovascular risk from, in diabetes mellitus, 961

Inflammatory demyelinating polyneuropathy, acute (Guillain-Barré syndrome), 709-711

Inflammatory mediator, aldosterone as, 448-449

Inflammatory myopathies, 904-906

Informed consent, communication about, 1134-1135

Inner ear, infections of, dizziness in, 607-611

Inotropic agents, for CHF
 classification of, 392
 digoxin as, 319-320. *See also* Digoxin, nonglycosidic, **391-418**
 indications for, 407-412
 limitations of, 408-412
 mechanisms of action of, 392-394
 phosphodiesterase inhibitors, 401-407
 sympathomimetics, 392-401

Insomnia, 817-820

Institute of Medicine
 minority women's health data from, 947
 women's health policies of, 924-925

Insulin, for diabetes mellitus, perioperative, 44, 177-181
 for infection risk reduction, 60
 in kidney failure, 205-206

Integrins, in CHF, 308, 313

Interdigital neuropathy (Morton's neuroma), 688-690

Interferon- β , for multiple sclerosis, 876, 883-884

Interleukin-6, cardiovascular risk from, in diabetes mellitus, 961

Intermittent pneumatic compression devices, for thromboembolism prophylaxis, 85-87

Internuclear ophthalmoparesis, in multiple sclerosis, 877-878

Intervertebral disk herniation, neck pain in, 654-656

Interview, patient, model for, 1118-1121

Isoflavones, for hot flashes, 1097-1099

Isometheptene mucate, for migraine headache, 594

Isoproterenol, for CHF, 401, 429

Isosorbide mononitrate, for CHF, pharmacogenomics of, 570-571

J

Jaundice, perioperative, 219-220

Jet lag, sleep disorders in, 823

K

Kava, perioperative, 49

Kidney

 age-related changes in, 276
 dysfunction/failure of.

See also Kidney failure.

 aldosterone role in, 448-449

 dopamine for, 399

 endothelin in, 463

 endothelin receptor antagonists for, 465

 in beta-blocker therapy, 364

 in CHF, **475-491**

 beta-blockers

 contraindicated in, 360-361

 diuretics for, 478-479

 natriuretic peptide system and, 485-488

 pathophysiology of, 475-478

 saluretic/aquaretic agents for, 480-485

 in sympathomimetic therapy, 394-395

 functional evaluation of,

 preoperative, 19-22

 toxicity to, chemotherapy-induced, perioperative management in, 251

Kidney failure, perioperative, **193-210**

 acute, 194-199

 epidemiology of, 194

 evaluation of, 195-196

 pathophysiology of, 194-195

 prevention of, 196-199

 end-stage, 199-206

 anemia treatment in, 203-204

 bleeding control in, 203-204, 239

 blood pressure control in, 204

 cardiac evaluation in, 200-202

 drug adverse reactions in, 204-205

 evaluation of, 199-200

- Kidney failure (*continued*)
 fluid and electrolytes in, 202-203
 glycemic control in, 205-206
- Kyphoplasty, in osteoporosis, 1055-1056
- L**
- Labor and delivery, HIV transmission in, 985-987
- Laboratory testing, preoperative, 7-40
 chest radiography, 28-29, 32-34
 coagulation tests, 14-17
 electrocardiography, 26, 28, 30-31
 electrolytes, 17-19
 glucose levels, 22-24
 hemoglobin, 9-11
 in elderly persons, 276-277
 kidney function tests, 19-22
 liver function tests, 24-25
 none, patient outcome and, 34
 normal vs. abnormal results in, 7-8
 platelet count, 11, 13-14
 protocols and policy for, 36
 rationale for, 8-9
 recommendations for, 34-35
 urinalysis, 24, 26-27
 white blood cell count, 11-12
- Labyrinthitis, dizziness in, 609, 611
- Lambert-Eaton syndrome, 249, 713
- Lamotrigine, for epilepsy
 advantages of, 741
 breast milk transmission of, 731
 disadvantages of, 741
 in mental retardation, 735-738
 in pregnancy, 731
 new-onset, 728
 side effects of, 728
- Latina women
 health facts about, 945
 hot flashes in, 1094
- Laughter, syncope associated with, 842-843
- Law of Laplace, in CHF, 307-308
- Lead poisoning, peripheral neuropathy in, 720
- LEARN tool, for cross-cultural communication, 1124
- Lee's index of cardiac risk, 112-116
- Leflunomide, for rheumatoid arthritis, perioperative, 55
- Left ventricular assist device, for CHF, ventricular remodeling during, 540-544
- Legal issues, in whiplash injury, 651
- Lepirudin, for thromboembolism prophylaxis, 93
- Lesbianism, 1086
- Leukoaraisosis, dizziness in, 619-620
- Levetiracetam, for epilepsy, 741
- Levodopa, for CHF, 399-400
- Levosimendan, for CHF, 403-404
- Levothyroxine, perioperative, 53, 182
- Lewy body disease, diffuse, 774-775
- Lhermitte's phenomenon, in multiple sclerosis, 877
- Light therapy, for circadian rhythm sleep disorders, 822-823
- Lipid-lowering therapy
 for cardiovascular risk reduction, in diabetes mellitus, 959
 for transient ischemic attack, 758
- Lipoprotein profiles, in diabetes mellitus, cardiovascular risk from, 958-959
- Lisinopril, for CHF, pharmacogenomics of, 571
- Literacy, health, patient-doctor communication and, 1124-1125
- Lithium, perioperative, 52
- Liver
 cytochrome P-450 system of, gender differences in, 932-933
 resection of, perioperative management in, 218-219
- Liver disease
 in CHF, beta-blockers contraindicated in, 360-361
 perioperative, 211-227
 alcoholic, 213
 chemotherapy-induced, 250-251
 cirrhosis, 213-217
 hepatitis, 212-213
 in laparoscopic procedures, 217-218
 in liver resection, 218-219
 intraoperative management of, 217
 obstructive jaundice, 220
 occult, 211-212
 postoperative jaundice, 221
 preoperative detection of, 24-25
- Lobular carcinoma in situ, cancer development from, 1013

- Lobular hyperplasia, atypical, cancer development from, 1013
- Loop diuretics, for CHF, 478-479
- Losartan, for CHF, versus captopril, 384-385
- Low back pain. *See* Back pain.
- Lower body parkinsonism, 797
- Lung
cancer of, gender differences in, 931-932
gender differences in, 931-932
- Lung expansion maneuvers, perioperative, 166-169
- Lyonization, 926
- M**
- Ma huang, perioperative, 49
- Magnetic resonance angiography
in brainstem stroke, 613
in carotid artery stenosis, 759
- Magnetic resonance imaging
in breast cancer screening, 1004
in central positional vertigo, 628
in disk herniation, 654
in epilepsy, 726
in interdigital neuropathy, 689
in leukoaraiosis, 619
in multiple sclerosis, 871, 874
in syncope, 46
in temporal lobe hemorrhage, 764-765
in transient ischemic attack, 756-757
in vestibular schwannoma, 614-615
- Maintenance of wakefulness test, in sleep disorders, 809
- Malnutrition, perioperative
in cancer, 244
in elderly persons, 279-280
- Mammography, for breast cancer screening, 998-1003
- Manipulation, for back pain, 648
- Mastectomy, for breast cancer axillary node biopsy with, 1021 prophylactic, 1009, 1012
- Median neuropathy, at wrist (carpal tunnel syndrome), 661-664, 706-708
- Medical consultation, preoperative, 1-6
benefits of, 5
comanagement in, 5
compliance with recommendations, 3-4
primary reason for, 2
principles of, 1-2
results of, 2-3
- Medications. *See* Drug(s).
- Melatonin, for sleep disorders, 822-823
- Memory loss, in diffuse Lewy body disease, 774-775
- Meniere's disease, dizziness in, 636-637
- Menopause
bone metabolism and, 927
depression in,
pharmacoendocrinologic interventions for, 1067-1069
HIV infection in, 992
hot flashes in. *See* Hot flashes.
urogenital complaints in, 1029-1037
- Menstrual cycle, seizures related to, 732
- Mental retardation, epilepsy in, 729-732, 735-738
- Meralgia paresthetica, 679-682
- Metabolic disorders, in cancer, perioperative, 246-247
- Metabolic modulators, for CHF, 493-507
biventricular pacemaker, 501-502
propionyl-L-carnitine, 494-499
ronalazine, 493-494, 500-501
trimetazidine, 493-494, 499-500
- Metalloproteinases, tumor necrosis factor- α effects on, 424-426, 429-430, 432
- Methamphetamine, for narcolepsy, 816
- Methimazole, perioperative, 53, 183
- Methotrexate
for multiple sclerosis, 881
for rheumatoid arthritis, perioperative, 55
- Methyldopa, for hot flashes, 1107
- Methylphenidate
for narcolepsy, 814, 816
for Tourette's syndrome, 772
- Methylprednisolone
for multiple sclerosis, 880
for optic neuritis, in multiple sclerosis, 871
- Metoprolol, for CHF, clinical trials of age factors in, 355
COMET, 344, 352

- Metoprolol (*continued*)
MERIT-HF, 344, 346-347, 351-352, 354-356
versus heart failure etiology, 354
versus other beta-blockers, 356-357
- Metronidazole
for bacterial vaginosis, 977
for trichomoniasis, 978
- Metyrosine, for pheochromocytoma, perioperative, 185
- Mexican American women, health facts about, 945
- Microbicides, for HIV transmission prevention, 992-993
- Micrographia, in Parkinson's disease, 781-782
- Micturition syncope, 843
- Midodrine
for orthostatic hypotension, 632-633, 855-856
for reflex syncope, 847
- Migraine headache
dizziness in, 634
features of, 592-593
prevention of, 597-599
rebound headache in, 599-602
versus stress headache, 591, 593-594, 596-597
without aura, versus sinus headache, 589-591
- Miller Fisher syndrome, 710
- Milrinone, for CHF, 401-403, 406
advanced, 410-411
costs of, 411
versus digoxin, 326
- Minority population. *See* Multicultural considerations.
- Mitogen-activated protein kinase, in CHF, 310-312
- Mitoxantrone, for multiple sclerosis, 880-881, 883
- Mitral valve
prolapse of, 859
regurgitation of
CHF in
resynchronization therapy effects on, 512-513
treatment of, 396
perioperative, 148
stenosis of, perioperative, 148
valvuloplasty of
in Batista operation, 535-536
ventricular remodeling and, 539-540
- Mivazerol, for coronary artery disease, perioperative, 128
- Modafanil, for narcolepsy, 814, 816
- Monoamine oxidase inhibitors, perioperative, 51
- Mood disorders. *See* Depression.
- Mood stabilizers, perioperative, 52
- Mortality
in calf deep venous thrombosis, 1162
in heparin-induced thrombocytopenia, 1216
in venous thromboembolism, 1183
in women
in cardiovascular disease, 955-956
multicultural considerations in, 943-947
- Morton's neuroma (interdigital neuropathy), 688-690
- Motor axonal neuropathy, acute, 710
- Motor tics, in Tourette's syndrome, 771-773
- Movement disorders, **771-791**
diffuse Lewy body disease, 774-775
dystonia, 775-777, 826, 878
essential tremor, 782-785
Huntington's disease, 788-789
multiple system atrophy, 786-788, 853-854
Parkinson's disease. *See* Parkinson's disease.
psychogenic tremor, 779-780
spinal myoclonus, 777-779
Tourette's syndrome, 771-773
- Multicultural considerations
in CHF drug treatment. *See* Pharmacogenomics, of CHF.
in perioperative thromboembolism risk, 80
in women's health, **939-954**
advocacy for, 952
African American, 943-945, 1094-1095
Alaskan, 946-947
American Indian, 946-947
Asian and Asian Pacific Islander, 945-946, 1094
assessment tools, 951-952
care disparities, 939-941
cause versus effect, 943
component variation, 942

- health data processing in, 947-948
 - history taking, 950-951
 - hot flash occurrence, 1093-1095
 - importance of, 940
 - in patient-doctor communication, 1123-1125
 - issues in, 939
 - Latina, 945, 1094
 - medical encounters in, 948-951
 - minority population statistics, 940
 - mortality, 943-947
 - osteoporosis, 1040
 - poverty and, 940
 - subcultural variation, 942
 - training on, 951-952
 - white, 943, 1094-1095
- Multiple sclerosis, 867-897**
- bladder dysfunction in, 886-888
 - bone loss in, 890
 - bowel dysfunction in, 888
 - classification of, 868
 - clinical features of, 878-880
 - clinically isolated syndrome in, 870-871
 - cognitive dysfunction in, 890
 - depression in, 889-890
 - diagnosis of, 869, 873-875, 891, 893-894
 - differential diagnosis of, 875
 - epidemiology of, 867
 - fatigue in, 889
 - gait dysfunction in, 884-885
 - genetics of, 867
 - histopathology of, 882-883
 - interferon neutralizing antibodies in, 883
 - internuclear ophthalmoparesis in, 877-878
 - magnetic resonance imaging in, 871, 874
 - myelitis in, 877
 - natural history of, 868
 - neuropathology of, 869-870
 - neuroradiology of, 871-872
 - optic neuritis in, 869-870
 - paroxysmal neurologic symptoms in, 878-880
 - perioperative, 260
 - primary progressive, 868
 - progressive relapsing, 868
 - relapse-remitting, 868, 877-881
 - secondary progressive, 868, 882-890
 - sexual dysfunction in, 889
 - spasticity in, 885-886
 - treatment of, 891, 893-894
 - relapse-remitting, 880-881
 - secondary progressive, 883-890
 - with clinically isolated syndrome, 875-876
 - versus sarcoidosis, 891-892
- Multiple sleep latency test, 808-809**
- Multiple system atrophy, 786-788, 853-854**
- Muscle(s)**
- atrophy of, in suprascapular neuropathy, 673-677
 - disorders of. *See* Myopathy(ies).
- Muscular dystrophy, myotonic, 901**
- Myelitis, in multiple sclerosis, 877**
- Myelopathy**
- cervical, 658
 - in spinal stenosis, foot drop in, 656-658
- Myelosuppression, chemotherapy-induced, perioperative management in, 251**
- Myoblast transplantation, for myopathies, 902-903**
- Myocardial infarction**
- CHF after, treatment of, 408-409
 - beta-blockers in, 359
 - dobutamine in, 395-396
 - surgical. *See* Surgery, for CHF.
 - in carotid endarterectomy, 262-263
 - sexual activity after, 1082
- Myocardial perfusion imaging, preoperative, in coronary artery disease, 124-125**
- Myocardium**
- aldosterone effects on, 446-447
 - fibrosis of, aldosterone effects on, 447
 - function of, endothelin in, 463
 - remodeling of. *See also* Ventricle(s), left, remodeling of.
 - endothelin receptors and, 468-469
- Myoclonus**
- in convulsive syncope, 843-844
 - spinal, 777-779
- Myocytes, cardiac, overload effects on, 307-308**
- Myopathy(ies), 899-907**
- acquired, 903-907
 - amyloid, 906-907
 - dysferlinopathy, 901-902
 - gene therapy for, 902
 - hypokalemic periodic paralysis, 900-901
 - idiopathic hyper-creatine kinase-emia, 899-900
 - in congestive heart failure, 304

- Myopathy(ies), (*continued*)
inflammatory, 904-906
inherited, 899-903
myoblast transplantation for, 902-903
myotonic muscular dystrophy, 901
quadriplegic, 904
stem cell therapy for, 903
steroid, 903-904
- Myosplint®, for CHF, 546-547
- MyoTech Cardiac Restoration System®,
for CHF, 548
- Myotonic muscular dystrophy, 901
- Myxedema coma, postoperative, 182
- N**
- Nadroparin, perioperative, in brain tumors,
1180-1181
- Naratriptan, for migraine headache,
594-595
- Nasogastric intubation, postoperative,
respiratory complications and, 161
- National Osteoporosis Foundation,
screening recommendations of, 1044
- National Research Act of 1974, 920
- National Women's Health Information
Center, minority women's health data
from, 947
- Natriuretic peptide system, CHF and, 397,
410, 476-477, 485-488
- Nebivolol, for CHF, clinical trials of,
SENIORS, 344
- Neck, dystonia of, 775-777
- Neck pain
anatomic considerations in, 643-645
epidemiology of, 642
evaluation of, 641
in disk herniation, 654-656
in whiplash injury, 650-652
pathophysiology of, 645-647
physical examination in, 647
risk factors for, 642-643
- Necrobiosis lipidica diabetorum, sensory
neuropathy in, 695-698
- Neosynephrine, for pseudosepsis syndrome,
411-412
- NEP 24.11 inhibitors, for CHF, 486-488
- Nerve conduction studies
in interdigital neuropathy, 689
in meralgia paresthetica, 682
in peroneal neuropathy, at fibular
neck, 678-679
in radial neuropathy, at spiral groove,
672-673
in tarsal tunnel syndrome, 684-685
in ulnar neuropathy
at elbow, 668
at wrist, 669-670
- Nesiritide, for CHF, 487
- Neuralgia
glossopharyngeal, syncope in, 843
postherpetic, 700
trigeminal, 711-712
- Neurally mediated syncope, 837-841
- Neuritis
optic, in multiple sclerosis, 870-871
vestibular, vertigo in, 607-611, 798
- Neurogenic claudication, in spinal stenosis,
652-654
- Neurohormonal function, digoxin effects
on, 323-324
- Neurologic disorders. *See also* Peripheral
neuropathy.
back pain, **641-660**
cerebrovascular disease, 732-735,
755-770
dizziness. *See* Dizziness.
entrapment neuropathies, **661-694**
epilepsy, **723-744**, 826-827
gait disorders, **793-801**, 884-885
headache. *See* Headache.
movement disorders. *See* Movement
disorders; Parkinson's disease.
multiple sclerosis, **867-897**
myopathies, **897-907**
neck pain, **641-660**
perioperative, **257-271**
brain tumors, 264-265
carotid disease, 258-259,
261-263
cerebrovascular disease, 257-258
delirium, 267-268
dementia, 259-260
hypertension, 266-267
hyponatremia, 268-269
in cancer, 249
multiple sclerosis, 260
parkinsonism, 261
postoperative respiratory
complications in, 156-157
routine drug regime, 49-50
seizures, 260-261
spinal, 264
subarachnoid hemorrhage,
263-264

- thromboembolism prophylaxis
 - in, 265-266
 - peripheral neuropathies, 695-721
 - sleep disorders, 803-833
 - syncope, 835-865
 - Neurologic surgery, perioperative management in
 - antibiotic prophylaxis in, 65-66
 - brain tumors, 264-265
 - carotid endarterectomy, 261-263
 - spinal, 264
 - subarachnoid hemorrhage, 263-264
 - Neuroma
 - acoustic, dizziness in, 614-615
 - Morton's (interdigital neuropathy), 688-690
 - Neuromuscular blocking agents, postoperative respiratory complications and, 161
 - Neuropathy. *See* Entrapment and compressive neuropathy; Peripheral neuropathy.
 - Neurotransmitters
 - gender differences in, 929
 - hot flashes and, 1093
 - in depression, in women, 1069-1070
 - New York Heart Association, cardiac risk classification of, 112-113
 - Nightmares, 825
 - Nitrates, for cardiac disorders, perioperative, 42
 - Nitroglycerin, for CHF, 406
 - Nitroprusside, for CHF, 397, 406
 - Nocturnal paroxysmal dystonia, 826
 - Non-24-hour sleep-wake syndrome, 823
 - Non-rapid eye movement (NREM) sleep, 803-804
 - Nonsteroidal anti-inflammatory drugs, perioperative, 44-45
 - kidney failure due to, 197
 - Norepinephrine
 - for CHF, 400-401
 - for pseudosepsis syndrome, 411-412
 - for septic shock, 410
 - hot flashes and, 1093
 - in CHF pathogenesis, 310, 319, 321-322
 - Normal pressure hydrocephalus, gait in, 796-797
 - Nortriptyline
 - for meralgia paresthetica, 706
 - for sensory neuropathy, 697-698
 - NREM (non-rapid eye movement) sleep, 803-804
 - Nuclear factor-kB, in tumor necrosis factor expression, 422
 - Numbness
 - in meralgia paresthetica, 679-682
 - in multiple sclerosis, 877
 - in radial neuropathy, at spiral groove, 670-673
 - in sensory neuropathy, 712-713
 - in spinal stenosis, 652-654
 - in tarsal tunnel syndrome, 682-685
 - in ulnar neuropathy, at elbow, 664-668, 708-709
 - Nutrition, for osteoporosis, 1049
 - Nutritional status
 - age-related changes in, 276
 - perioperative
 - in cancer, 244
 - in elderly persons, 280-281
 - respiratory complications and, 155-156
 - Nystagmus
 - in benign paroxysmal vertigo, 624
 - in central positional vertigo, 627-629
-
- O**
- Obesity
 - cardiovascular risk from, in diabetes mellitus, 960
 - perioperative thromboembolism risk in, 81
 - sleep apnea in, 810-812
 - Obstetrics, antibiotic prophylaxis for, 63-66
 - Obstructive jaundice, perioperative, 219
 - Obstructive sleep apnea, 809-812, 821
 - Obstructive sleep apnea-hypopnea syndrome, 810-812
 - Office of Research on Women's Health, women's health policies of, 924
 - Olivopontocerebellar degeneration (multiple system atrophy), 786-788, 853-854
 - Omapatrilat, for CHF, 487-488
 - Oophorectomy, for breast cancer prevention, 1009, 1012

- Ophthalmic procedures, antibiotic prophylaxis for, 65-66
- Ophthalmoparesis, internuclear, in multiple sclerosis, 877-878
- Opportunistic infections, in HIV infection, 991
- Optic neuritis, in multiple sclerosis, 870-871
- Oral contraceptives
 antiepileptic drug interactions with, 729-730
 iliofemoral deep venous thrombosis in, thrombolytic therapy for, **1165-1177**
 antagonist's perspective on, 1169-1174
 protagonist's perspective on, 1165-1169
 in factor V Leiden heterozygosity, **1225-1236**
 antagonist's perspective on, 1231-1235
 protagonist's perspective on, 1225-1231
 perioperative, 54-55
- Orgasmic disorder, 1080-1081
- Orthopedic procedures
 antibiotic prophylaxis for, 65-67
 thromboembolism prophylaxis for, 94-95
- Orthosis, ankle foot, for multiple sclerosis, 885
- Orthostatic hypotension, 632-633, 848-859
 differential diagnosis of, 856
 idiopathic, 856-859
 in acute and subacute neuropathy, 852-854
 in chronic autonomic neuropathy, 849-852
 in paraneoplastic syndromes, 853
 in parkinsonism, 853-854
 testing in, 854-855
 treatment of, 855-856
- Orthostatic tremor, gait in, 800-801
- Osteomyelitis, back pain in, 649-650
- Osteoporosis, **1039-1063**
 bone mass measurement in, 1041-1042
 diagnosis of, 1041-1042
 epidemiology of, 1040
 in multiple sclerosis, 890
 pathogenesis of, 1040-1041
 postoperative, in elderly persons, 279
 risk factors for, 1042-1043
 screening for, 1043-1044
 treatment of, 1043-1057
 behavioral modification in, 1049
 bisphosphonates in, 1046, 1048, 1052-1053
 calcitonin in, 1047-1048, 1053-1054
 clinical considerations in, 1056
 clinical trial evaluations, 1044-1045
 combination therapies in, 1055
 hormones in, 1046, 1048-1049
 monitoring of, 1056-1057
 nutritional, 1049
 parathyroid hormone in, 1047-1048, 1054-1055
 perioperative management of, 46, 48
 selective estrogen receptor modulators in, 1046, 1048, 1050-1052
 surgical, 1055-1056
- Otoconia, repositioning of, for benign paroxysmal vertigo, 624-627
- Ototoxicity
 drugs causing, 621-623
 vestibular hypofunction in, 616
- Overload, in CHF, cardiomyopathy in, 307-308
- Oxcarbazepine
 for epilepsy, 728, 741
 for trigeminal neuralgia, 711
- Oxybutynin, for bladder dysfunction, in multiple sclerosis, 887
- Oxygen consumption, maximal, cardiovascular risk and, in diabetes mellitus, 962-964
- Oxygen therapy, for postoperative infection risk reduction, 60-61
- P**
- Pacemakers
 biventricular. *See* Cardiac resynchronization therapy.
 for reflex syncope, 847
 perioperative management with, 146-147
- Pain
 abdominal, in porphyria, 718
 ankle, in tarsal tunnel syndrome, 682-685
 back. *See* Back pain.
 buttock, in piriformis syndrome, 686-688
 chest, in herpes zoster, 698-700

- discussion of, communication techniques for, 1128-1132
- elbow, in ulnar neuropathy, 664-668, 708-709
- facial
- in Bell's palsy, 700-703
 - in trigeminal neuralgia, 711-712
- foot. *See* Foot pain.
- headache. *See* Headache.
- management of
- in cancer, perioperative management and, 244-245
 - postoperative, respiratory complications and, 161-162
- neck. *See* Neck pain.
- neuropathic, 695-698
- response to, gender differences in, 929-930
- shoulder
- in brachial plexopathy, 714-716
 - in suprascapular neuropathy, 673-676
- syncope in, 843
- thigh, in meralgia paresthetica, 679-682, 704-706
- wrist, in carpal tunnel syndrome, 661-664, 706-708
- Panic attacks, dizziness in, 634-636
- Paralysis
- hypokalemic periodic, 900-901
 - in Guillain-Barré syndrome, 709-711
- Paraneoplastic syndromes
- acute autonomic neuropathy in, 853
 - perioperative, 249
 - sensory neuropathy in, 712-713
- Parasomnias, 824-826, 831-832
- arousal disorders, 824-825, 831
 - in REM sleep, 825-826, 832
- Parathyroid hormone
- alterations of, osteoporosis in, 1040
 - for osteoporosis, 1047-1048, 1054-1055
- Pargyline, perioperative, 51
- Parkinsonism
- atypical (multiple system atrophy), 786-788, 853-854
 - autonomic failure and, 853-854
 - lower body, 797
 - vascular, 797
- Parkinson's disease
- advanced, 785-786
 - early, 781-782
 - gait in, 794-795
 - orthostatic hypotension in, 853-854
 - parasomnia in, 825-826
 - perioperative, 49-50, 261
 - versus diffuse Lewy body disease, 774-775
- Parkinson's plus (multiple system atrophy), 786-788, 853-854
- Paroxetine
- for depression, 1072-1073
 - for hot flashes, 1104
 - for reflex syncope, 847
 - perioperative, 51-52
- Paroxysmal nocturnal dyspnea, in sleep apnea, 810-812
- Parsonage Turner syndrome, 714-716
- Partial thromboplastin time, preoperative, 14, 16-17, 235-236
- Patient education, on women's health, resources for, 1138-1140
- PD 156,707 (endothelin receptor antagonist), myocardial remodeling and, 469
- Pediatric patients
- HIV infection treatment in, 992
 - HIV transmission to, 985-987
- Pelvic floor muscular tone, loss of, in menopause, 1030
- Pelvic inflammatory disease, in HIV infection, 979
- Penicillin(s), for postoperative infection risk reduction, allergy considerations in, 62
- Pentasaccharides, for thromboembolism prophylaxis, 90-93
- Pentoxifylline, for CHF, tumor necrosis factor- α levels and, 429
- Peptide growth factors, in CHF, 311
- Performance status, in cancer, perioperative management and, 244
- Pericardial effusion, in cancer, cardiopulmonary obstruction and, 245-246
- Perilymphatic fistula, 629-630
- Periodic limb movement disorder, 820-823
- Periodic paralysis, hypokalemic, 900-901
- Perioperative management
- antimicrobial, **59-75**
 - in anemia. *See* Anemia, perioperative.
 - in bleeding disorders, 235-239
 - in cancer, **243-256**
 - in elderly persons, **273-289**

- Perioperative management (*continued*)
in endocrine dysfunction, 175-192
in heart disease
 coronary artery, 111-136
 nonischemic, 137-152
in kidney failure, 193-210
in liver disease, 24-25, 211-227
in neurologic disease.
 See Neurologic disorders, perioperative.
in pulmonary disease, 153-173.
 See also Respiratory disorders, perioperative management of.
laboratory testing, 7-40
medical consultation in, 1-6
of usual medications, 41-57
venous thromboembolism prophylaxis, 77-110
- Peripheral arterial resistance, in CHF, 476
- Peripheral neuropathy, 695-721
 Bell's palsy, 700-703
 brachial plexopathy, 714-716
 carpal tunnel syndrome, 661-664, 706-708
 Charcot-Marie-Tooth disease, 703-704, 799
 Guillain-Barré syndrome, 709-711
 herpes zoster, 698-700
 in porphyria, 716-720
 in thallium poisoning, 713-714
 lateral femoral cutaneous (meralgia paresthetica), 679-682, 704-706
 Miller Fisher syndrome, 710
 motor axonal, 710
 sensory, 695-698
 sensory neuronopathy, 712-713
 trigeminal neuralgia, 711-712
 ulnar neuropathy
 at elbow, 664-668, 708-709
 at wrist, 668-670
- Peripheral vascular disease, in CHF, beta-blockers contraindicated in, 361
- Peroneal neuropathy, at fibular neck, 677-679
- Phalen's maneuver, in carpal tunnel syndrome, 661-663, 707
- Pharmacogenomics, of CHF, 569-579
 adrenergic system gene polymorphisms, 355, 571-573
 aldosterone synthase polymorphisms, 573
 bradykinin receptor gene polymorphisms, 573
 future directions in, 573-577
 renin-angiotensin system gene polymorphisms, 570-571
- Pharmacokinetics, in elderly persons, perioperative management and, 277
- Phenelzine, perioperative, 51
- Phenobarbital, for epilepsy
 advantages of, 741
 breast milk transmission of, 731
 disadvantages of, 741
 in elderly persons, 732-735
 side effects of, 728
- Phenothiazines, perioperative, 52
- Phenoxybenzamine, for pheochromocytoma, perioperative, 185
- Phenylephrine, for CHF, 400
- Phenytoin, for epilepsy
 advantages of, 741
 breast milk transmission of, 731
 disadvantages of, 741
 new-onset, 728
 side effects of, 728
- Pheochromocytoma, perioperative, 183-186
- Phlegmasia cerulea dolens, thrombolytic therapy for, 1170-1171
- Phosphodiesterase inhibitors, for CHF, 401-407, 429
- Photosensitivity, in porphyria, 716-720
- Physical activity
 counseling on, communication techniques for, 1126-1128
 for hot flashes, 1109
 reduced, cardiovascular risk from, in diabetes mellitus, 962
- Phytoestrogens
 for hot flashes
 characteristics of, 1096-1097
 detrimental effects of, 1098-1100
 efficacy of, 1100
 mechanism of action of, 1097-1098
 for urogenital complaints, 1034
- Pimozide, for Tourette's syndrome, 772-773
- Pinobendan, for CHF, 403-404, 407
- Piriformis syndrome, 686-688
- Plasmid DNA, as gene transfer vector, for CHF, 555
- Plasminogen activator inhibitor
 aldosterone effects on, 449
 cardiovascular risk and, in diabetes mellitus, 960-961

- Platelet aggregation assay, in heparin-induced thrombocytopenia, 1218
- Platelet count, preoperative, 11, 13-14
- Platelet factor 4, in heparin-induced thrombocytopenia, 1216-1218
- PLISSIT model, for sexual problem assessment, 1087
- Pneumatic compression devices, intermittent, for thromboembolism prophylaxis, 85-87
- Pneumonia, postoperative, in elderly persons, 281
- Poisoning, peripheral neuropathy in
 lead, 720
 thallium, 713-714
- Polymyositis, 904-906
- Polysomnography, in sleep disorders, 806-807
- Popliteal vein thrombosis, warfarin for, precolonoscopy management in, **1205-1214**
- Porphyria, peripheral neuropathy in, 716-720
- Positive pressure breathing, intermittent, postoperative, 168-169
- Postoperative Pneumonia and Respiratory Failure Risk Index, 162-163
- Postthrombotic syndrome, 1165-1169, 1173-1174
- Potassium, preoperative measurement of, 17-18
- Potassium canrenoate, for CHF, 453, 485
- Potassium channels, as gene transfer targets, for CHF, 561-562
- Poverty, women's health and, 940
- Pramipexole
 for Parkinson's disease, 781
 for restless legs syndrome, 820
- Preconception counseling, in HIV infection, 992
- Prediabetic state, cardiovascular risk in, 965
- Prednisone
 for Bell's palsy, 702
 for inflammatory myopathy, 906
 for multiple sclerosis, 873
 for temporal arteritis, 603
 for vestibular neuritis, 608, 611
 perioperative, 186-189
- Pregnancy
 epilepsy in, 729-732
 HIV transmission in, 985-987
 immune system changes in, 931
- Premenstrual dysphoric disorder
 epidemiology of, 1066
 neurotransmitter levels in, 1070
 pathophysiology of, 1066
- Pressure ulcers, postoperative, in elderly persons, 279
- Primidone
 for epilepsy, breast milk transmission of, 731
 for essential tremor, 783-784
- Progesterone
 depressogenic effects of, 1067
 for CHF, 452-453
 for osteoporosis, 1048-1049
- Progressive supranuclear palsy, gait in, 795-796
- Proliferative signaling, in CHF, 308-314
- Promethazine, for vestibular neuritis, 608-609
- Propantheline, for bladder dysfunction, in multiple sclerosis, 887
- Propionyl-L-carnitine, for CHF, 494-499
- Propranolol
 for essential tremor, 784
 for hyperthyroidism, perioperative, 182-183
- Propylbutyl dopamine, for CHF, 399
- Propylthiouracil, perioperative, 53, 183
- Prosthetic heart valves
 antibiotic prophylaxis with, 67-70
 thromboembolism prophylaxis with, 99-100
- Protectionism, in clinical studies, 919-922
- Protein C deficiency, testing for, 1238-1240, 1243-1244, 1246-1247
- Protein S deficiency, testing for, 1238-1241, 1243-1244, 1246-1247
- Prothrombin mutations, testing for, 1239-1241, 1243
- Prothrombin time, preoperative, 14-15, 17, 235-236
- Pseudoagoraphobia, gait in, 800
- Pseudoseizures, 742

- Pseudosepsis syndrome, in CHF, treatment of, 411-412
- Psychiatric disorders, drugs for, perioperative management of, 50-53
- Psychogenic disorders
dizziness, 620-621, 634-636
gait, 799-800
insomnia, 817-818
mimicking syncope, 856
tremor, 779-780
- Public health policy, protectionism versus access in, 919-922
- Public Health Service Act of 1944, 919
- Puerto Rican women, health facts about, 945
- Pulmonary artery catheter, in coronary artery disease, preoperative, 130
- Pulmonary disorders. *See* Respiratory disorders.
- Pulmonary embolism. *See also* Venous thromboembolism.
acute
 echocardiography in, **1251-1262**
 antagonist's perspective on, 1256-1259
 protagonist's perspective on, 1251-1256
 patent foramen ovale and, 1255
 pathophysiology of, 1252
 right heart thrombi in, 1255-1256
 risk stratification in, 1254-1255
after brain tumor surgery, 1180, 1182-1185
in calf deep vein thrombosis, 1161
prophylaxis for, vena caval filters for.
 See Vena cava, inferior, filters in.
- Pulmonary function testing, preoperative, 163-164
- Pulse, in congestive heart failure, 304
- Pump dysfunction, in congestive heart failure, 304
- Pure autonomic failure, orthostatic hypotension in, 854

Q

- Quadriplegic myopathy, 904
- Quality of life issues, in congestive heart failure, 411
- Quality of Life Questionnaire-Core 30, 1138
- Questionnaires, for sleep disorders, 805-806

- Quetiapine, for Parkinson's disease, 785-786

R

- Racial factors. *See* Multicultural considerations.
- Radial neuropathy, at spiral groove, 670-673, 719-720
- Radiation therapy, for cancer
breast, 1016-1018, 1022
perioperative management of, 252-253
- Radiocontrast agents, kidney failure due to, 197
- Raloxifene
for breast cancer prevention, 1009-1010
for osteoporosis, 1046, 1048, 1050-1051
perioperative, 46
- Ramsay Hunt syndrome, dizziness in, 609, 611
- Ranolazine, for CHF, versus dobutamine, 397-398
- Rapid eye movement (REM) sleep, 803-804, 832
parasomnias in, 825-826, 832
- Reflex, vestibulo-ocular, in dizziness, 607-608
- Reflex syncope, 836-837, 846-847
- Rehabilitation, vestibular, in vestibular hypofunction, 616-618
- Relaxation techniques, for hot flashes, 1108-1109
- REM (rapid eye movement) sleep, 803-804
parasomnias in, 825-826, 832
- Remicade, for CHF, tumor necrosis factor- α levels and, 431
- Renal blood flow, in CHF, 476-477, 483
- Renal failure. *See* Kidney failure.
- Renin-angiotensin system. *See also* Aldosterone.
gene polymorphisms of, CHF
pharmacogenomics and, 570-571
- RES-701-1 (endothelin receptor antagonist), for CHF, 469
- Respiratory disorders
perioperative management of
drugs for, 43-44

- in cancer, 245-246, 250
- in elderly persons, 279
- radiation-induced, 253
- preoperative evaluation of, 28-29, 32-34, **153-173**
 - anesthesia-related risk factors in, 160-161
 - goals of, 154
 - literature search on, 154
 - operation-related risk factors in, 157-160
 - patient-related risk factors in, 155-157
 - postoperative care-related risk factors in, 161-162
 - risk indices for, 162-163
 - risk reduction strategies based on, 165-169
 - tests for, 163-164
- Respiratory function, measurement of, in sleep disorders, 806-807
- Respiratory system, age-related changes in, 276
- Restless legs syndrome, 820-823
- Resynchronization therapy. *See* Cardiac resynchronization therapy.
- Reteplase, for deep venous thrombosis bleeding complications from, 1172 costs of, 1171
- Revascularization, myocardial, for CHF, 527-529
- Rheumatic disease, perioperative management of, 55, 147
- Rheumatoid arthritis
 - perioperative drugs for, 55
 - sexual activity with, 1083
- Risedronate, for osteoporosis, 1046, 1048, 1052-1053
- Risperidone, perioperative, 52
- Rizatriptan, for migraine headache, 594-596
- Ronalazine, for CHF, 493-494, 500-501
- Ropinirole, for Parkinson's disease, 785-786
- S**

- St. John's wort
 - for hot flashes, 1105
 - perioperative, 49
- Salt retention, in CHF. *See* Kidney, dysfunction/failure of, in CHF.
- Saluretic agents, for CHF, 480-485
- Samoa women, health facts about, 946
- Sarcoidosis, versus multiple sclerosis, 891
- Sarcolemmopathy, 901-902
- Saturday night palsy, radial neuropathy in, 670-673, 719-720
- Schwannoma, vestibular, dizziness in, 614-615
- Sciatic neuropathy, proximal, piriformis syndrome in, 686-688
- Screening
 - for breast cancer, 998-1004
 - for osteoporosis, recommendations for, 1043-1044
 - for specific conditions, tools for, 1136-1138
- Sedentary lifestyle, cardiovascular risk from, in diabetes mellitus, 962
- Seizures
 - catamenial, 732
 - lone, versus syncope, 847-848
 - perioperative, 50, 260-261
 - recurrent. *See* Epilepsy.
 - versus convulsive syncope, 843-844
- Selective estrogen receptor modulators, for osteoporosis, 1046, 1048, 1050-1052
- Selective serotonin reuptake inhibitors
 - for depression, 1070, 1072-1073
 - for hot flashes, 1103-1105
 - perioperative, 51-52
- Selegiline, perioperative, 49-50
- Sensory neuronopathy, 712-713
- Sensory neuropathy
 - gait in, 799
 - of foot, 695-698
- Sepsis, perioperative, prevention of. *See* Antibiotic prophylaxis.
- Septic shock
 - dopamine for, 399
 - treatment of, 410
 - vasopressors for, 410
- SERCA2a gene, transfer of, for CHF, 557-559
- Serine protease inhibitors, testing for, 1238
- Serotonin, hot flashes and, 1093
- Serotonin release assay, in heparin-induced thrombocytopenia, 1217-1218
- Sertraline, perioperative, 51-52

- Sex chromosomes, in gender-specific medicine, 925-926
- Sex hormone-binding globulin, phytoestrogen action on, 1098
- Sexual arousal disorder, 1080
- Sexual aversion disorder, 1081
- Sexual desire, hypoactive, 1080
- Sexual dysfunction, in multiple sclerosis, 889
- Sexual response cycle, female, 1079-1080
- Sexuality, female. *See* Female sexuality.
- Sexually transmitted diseases
HIV infection as. *See* Human immunodeficiency virus infection.
HIV infection coinfection with, 975-983, 993-994
- SF-36 health survey, 1137-1138
- Shift work, sleep disorders in, 823
- Shingles, 698-700
- Shock
cardiogenic, dopamine for, 398-399
septic, treatment of, 399, 410
- Shoulder
brachial plexopathy in, 714-716
suprascapular neuropathy in, 673-677
- Shunt, ventriculoperitoneal, for normal pressure hydrocephalus, 797
- Shy-Drager syndrome (multiple system atrophy), 786-788, 853-854
- Sickle cell disease, anemia in, perioperative, 233
- Signaling, in CHF
functional, 308-310, 312
proliferative, 308-314
- Simvastatin, for cardiovascular risk reduction, in diabetes mellitus, 959
- Sinus headache, versus migraine headache, 589-591
- Sitaxentan, for CHF, 467
- Situational syncope, 842-843
- Skeletal system, gender differences in, 926-927
- Sleep
non-rapid eye movement (NREM), 803-804
physiology of, 803-804
rapid eye movement (REM), 803-804, 832
- Sleep apnea
central, with hypopnea, 813-814
mixed, 810-812
obstructive, 809-812, 821
postoperative respiratory complications and, 156
- Sleep disorders, **803-833**
apnea. *See* Sleep apnea.
breathing disorders, 809-814
central sleep apnea-hypopnea syndrome, 813-814
mixed sleep apnea, 810-812
obstructive sleep apnea, 809-812
circadian rhythm disorders, 822-823, 831
classification of, 805, 831-833
diagnosis of, 805-809
dysomnias, 831
epilepsy, 826-827
extrinsic, 831
headache, 826
hypersomnias, 814-817
insomnia, 817-820
intrinsic, 831
light therapy for, 822-823
medical disciplines for, 804-805
melatonin and, 822-823
narcolepsy, 814-816
neurologic, 832
parasomnias, 824-826, 831-832
periodic limb movement disorder, 820-823
restless legs syndrome, 820-823
sleep physiology and, 803-804
- Sleep hypoventilation syndrome, 813
- Sleep terrors, 824-825
- Sleepiness. *See* Somnolence.
- Sleepwalking, 825, 831
- Smoking
cardiovascular risk from, in diabetes mellitus, 959
harmful effects of, gender differences in, 931-932
in Alaskan native women, 946
postoperative respiratory complications and, 156, 165-166
- Sodium/calcium exchanger, in digoxin action, 319-320
- Sodium/potassium ATPase (sodium pump)
digoxin effects on, 318-319
in aldosterone secretion, 483-484
- Somnambulism, 825

- Somnolence, daytime
after brain injury, 817
in idiopathic hypersomnia, 816-817
in narcolepsy, 814-816
in obstructive sleep apnea, 809-812
- Soybean products, for hot flashes, 1097, 1100
- Spasticity, in multiple sclerosis, 885-886
- Spinal cerebellar ataxia, gait in, 797-798
- Spinal cord compression, in cancer, perioperative management in, 249
- Spinal myoclonus, 777-779
- Spine
pain related to. *See* Back pain; Neck pain.
stenosis of
foot drop in, 656-658
numbness in, 652-654
surgery on, perioperative management in, 264
- Spirometry
postoperative, 166-169
preoperative, 163-164
- Spironolactone, for CHF, 314, 479, 484-485
clinical studies of, 442
indications for, 449-450
mechanisms of action of, 447-449
pathologic basis for, 443-447
regimen for, 450-451
- Statins, for transient ischemic attack, 758
- Stem cell therapy, for myopathy, 903
- Stent placement, in coronary artery disease, preoperative, 129-130
- Stenting, carotid, 760-761
- Steroids. *See* Corticosteroids.
- Stockings, elastic, for thromboembolism prophylaxis, 85
- Streptokinase, for iliofemoral deep venous thrombosis, 1169
- Stress, surgical, corticosteroid
+ supplementation in, 186-189
- Stress headache, versus migraine, 591, 593-594, 596-597
- Stress incontinence, in menopause, 1031-1032
- Stress testing, preoperative, in coronary artery disease, 123-124
- Striatonigral degeneration (multiple system atrophy), 786-788, 853-854
- Stroke
acute, 761-762
brainstem, 611-614
epilepsy in, 732-735
in carotid endarterectomy, 262-263
minor, 755-758
perioperative, 249, 257-258
sexual activity after, 1083
versus syncope, 856
- Subarachnoid hemorrhage, perioperative management in, 263-264
- Succinylcholine, in kidney failure, 205
- Sumatriptan, for migraine headache, 594-597
- Superior canal dehiscence, dizziness in, 630-632
- Suprascapular neuropathy, 673-677
- Supraventricular arrhythmias, perioperative, 143-147
- Surgery. *See also* Perioperative management.
for CHF, **523-552**
Acorn cardiac support device, 545-546
Batista operation, 534-539
CardioClasp[®], 547
Dor procedure, 530-534
left ventricular assist devices, 540-544
mitral valve repair, 539-540
myocardial revascularization, 527-529
Myosplint[®], 546-547
MyoTech Cardiac Restoration System[®], 548
ventricular remodeling
pathophysiology and, 524-527
ventricular restoration, 529-534
- Sympathetic activity, in CHF, 476
- Sympathomimetics, for CHF, 392-401
dobutamine. *See* Dobutamine.
dopamine, 393-394, 398-399, 401
dopexamine, 399-400
ibopamine, 400
mechanisms of action of, 392-394
norepinephrine, 400-401
- Synchronization, of systole, in CHF. *See* Cardiac resynchronization therapy.
- Syncope, **835-865**
convulsive, 843
cough, 842-843
diagnosis of, 845-846

Syncope, (*continued*)

- in carotid sinus hypersensitivity, 841-842
- in glossopharyngeal neuralgia, 843
- in orthostatic hypotension, 632-633, 848-859
 - differential diagnosis of, 856
 - idiopathic, 856-859
 - in acute and subacute neuropathy, 852-854
 - in chronic autonomic neuropathy, 849-852
 - in paraneoplastic syndromes, 853
 - in parkinsonism, 853-854
 - testing in, 854-855
 - treatment of, 855-856
- in seizures, 847-848
- laughter-associated, 842-843
- micturition, 843
- neurally mediated, 837-841
- reflex, 836-837, 846-847
- situational, 842-843

Syndrome of inappropriate antidiuretic hormone secretion, perioperative, 246-247, 268-269

Syphilis, in HIV infection, 982-983

Systole, synchronization of, in CHF. *See* Cardiac resynchronization therapy.

T

T lymphocytes, infiltration of, in multiple sclerosis, 869-870

Tachycardia, in orthostatic intolerance, 857

TAK-044 (endothelin receptor antagonist), for CHF, 469

Tamoxifen

- for breast cancer prevention, 1008-1010
- for osteoporosis, 1046, 1048, 1050-1051
- perioperative, 46

Tarsal tunnel syndrome, 682-685

Temazepam, for insomnia, 818-819

Temporal arteritis, headache in, 602-604

Temporal lobe

- excision of, for epilepsy, 739-740
- hemorrhage of, 764-767
- sclerosis of, epilepsy in, 738-740

Tension-type headache, features of, 592-593

Teratogenesis, of antiepileptic drugs, 730-731

Terminal illness, counseling on, communication techniques for, 1132-1134

Test of Functional Health Literacy in Adults, 1125

Testosterone

- for sexual dysfunction, in females, 1084-1085
- immune system effects of, 930-931

Tezosentan

- for CHF, 467
- for kidney failure, 465

Thalamotomy, for essential tremor, 784

Thalamus, stimulation of, for essential tremor, 783-784

Thalassemia, perioperative, 233

Thalidomide, for CHF, tumor necrosis factor- α levels and, 429

Thallium poisoning, acute neuropathy in, 713-714

Thermoregulatory instability, hot flashes in, 1092-1093

Thiazide diuretics, for CHF, 479

Thigh pain, in meralgia paresthetica, 679-682, 704-706

Thirst, in congestive heart failure, 304

Thoracic procedures, antibiotic prophylaxis for, 65, 67

Thrombocytopenia

- heparin-induced, 1208, **1215-1224**
 - clinical features of, 1219
 - description of, 1215-1216
 - diagnosis of, 1219-1220
 - differential diagnosis of, 1219-1220
 - epidemiology of, 1218-1219
 - laboratory testing for, 1217-1222
 - pathophysiology of, 1216
 - prevention of, 1219
- perioperative, 238-239
- preoperative detection of, 11, 13-14

Thrombocytosis, in cancer, perioperative, 248

Thromboembolism, venous. *See* Venous thromboembolism.

Thrombolytic therapy

- for deep venous thrombosis
 - costs of, 1171
 - physician experience with, 1173

- for iliofemoral deep venous thrombosis, in oral contraceptive use, **1165-1177**
 - antagonist's perspective on, 1169-1174
 - protagonist's perspective on, 1165-1169
- for stroke, 761-762
- Thrombophilia
 - acquired, 1244-1245
 - as perioperative thromboembolism risk, 80-81
 - testing for, in first idiopathic deep venous thrombosis
 - antagonist's perspective on, 1242-1248
 - protagonist's perspective on, 1237-1242
- Thyroid gland and hormones
 - gender differences in, 928
 - perioperative considerations in, 53, 181-183
- Tiagabine, for epilepsy, 741
- Tibial neuropathy (tarsal tunnel syndrome), 682-685
- Tibolone, for sexual dysfunction, in females, 1085-1086
- Ticlopidine, perioperative, 45
- Tics, in Tourette's syndrome, 771-773
- Tilt table testing, in syncope, 845-846
- Tinel's sign, in carpal tunnel syndrome, 661-663, 707
- Tinzaparin, for thromboembolism prophylaxis, 90-93, 101
- Tissue factor pathway inhibitor, testing for, 1238
- Tissue plasminogen activator
 - for deep venous thrombosis, bleeding complications from, 1172
 - for stroke, 761-762
- Tizanidine, for spasticity, in multiple sclerosis, 885-886
- Tolterodine, for bladder dysfunction, in multiple sclerosis, 887
- Tolvaptan, for CHF, 481
- Topiramate
 - for epilepsy, 735-738, 741
 - for migraine headache, 599
- Torsemide, for CHF, 478-479
- Torticollis, 775-777
- Tourette's syndrome, 771-773
- Tracheostomy, for sleep apnea, 810, 812
- Transfusions, for anemia, perioperative, 231-235
 - autologous, 233-234
 - evidence for, 231-232
 - guidelines for, 234-235
 - in cardiovascular disease, 232-233
 - in nutritional deficiencies, 233
 - in thalassemia, 233
 - sickle cell, 233
- Transient ischemic attacks, 755-758
 - dizziness in, 633
 - perioperative, 257-258
- Translators, for patient-doctor encounters, 949-950
- Transplantation, heart
 - bridge to, dobutamine for, 396-398
 - in CHF, 528-529
- Tremor
 - essential, 782-785
 - in cervical dystonia, 776-777
 - orthostatic, gait in, 800-801
 - psychogenic, 779-780
- Triamterene, for CHF, 479
- Trichomoniasis, in HIV infection, 977-978
- Tricyclic antidepressants, perioperative, 50-51
- Trigeminal neuralgia, 711-712
- Triggers, of migraine headache, 591
- Trihexyphenidyl, for dystonia, 776-777
- Trimetazidine, for CHF, 493-494, 499-500
- Triptans, for migraine headache, 594-597
- Trust, in minority population, 941
- Tumor(s), brain
 - perioperative management in, 264-265
 - thromboprophylaxis for, **1179-1187**
- Tumor necrosis factor- α
 - in CHF
 - biology of, 420
 - in animal models, 422-428
 - in human cardiovascular disease, 421-422
 - inhibitors of
 - failure of, 431-434
 - in animal models, 424, 426

Tumor necrosis factor- α (*continued*)
in human studies, 426,
429-434
receptors for, for CHF, 424-434

Tumor necrosis factor- α -converting
enzyme, action of, 420, 422

Tussive (cough) syncope, 842-843

U

Uhthoff phenomenon, in multiple sclerosis,
877

Ulcer(s), genital, in HIV infection,
982-983

Ulnar neuropathy
at elbow, 664-668, 708-709
at wrist, 668-670

Ultrasonography
in bone mass density measurement,
1042
in breast cancer screening, 1003-1004

Uremia. *See* Kidney failure, perioperative,
end-stage.

Urethral dysfunction, in menopause, 1030

Urinalysis, preoperative, 24, 26-27

Urinary tract infections, postoperative, in
elderly persons, 281

Urination, syncope in, 843

Urodilatin, 485-486

Urogenital complaints, in menopause,
1029-1037
genital atrophy, 1029-1030
pelvic floor, 1030
urinary tract, 1030-1032
vulvovaginal, 1029-1030
Women's Health Initiative report on,
1032-1034

Urokinase, for deep venous thrombosis
bleeding complications from, 1172
costs of, 1171

Urologic procedures, antibiotic prophylaxis
for, 67

Uvulopalatopharyngoplasty, for sleep
apnea, 812

V

Vaccines, for HIV, 993

Vagal nerve stimulation therapy, for
epilepsy, 737

Vaginismus, 1081

Vaginitis
candidal, in HIV infection, 978-979
Trichomonas, in HIV infection,
977-978

Vaginosis, bacterial, in HIV infection,
976-977

Valacyclovir
for Bell's palsy, 702
for herpes zoster, 699

Valerian, perioperative, 49

Valproic acid
for epilepsy
breast milk transmission of, 731
in elderly persons, 732-735
in mental retardation, 735-738
in pregnancy, 729
new-onset, 728
side effects of, 728, 732
for spinal myoclonus, 778

Valsalva's maneuver, syncope in, 842-843

Valsartan, for CHF, 385

Valvular heart disease
heart failure in, treatment of, 396
perioperative management in, 147-149
prosthetic valves for,
thromboembolism prophylaxis
with, 99-100

Vascular parkinsonism, 797

Vascular procedures, antibiotic prophylaxis
for, 65, 67

Vascular smooth muscle cells, aldosterone
effects on, 445

Vasoconstriction, endothelin in, 459-463

Vasodilators, for CHF, adverse effects of,
313-314

Vasomotor flushing. *See* Hot flashes.

Vasopeptide inhibitors, for CHF, 487-488

Vasopressin receptor antagonists, for CHF,
480-481

Vasovagal (neurally mediated) syncope,
837-841

Vena cava, inferior, filters in, for
thromboembolism prophylaxis, 87
anticoagulation with, **1189-1203**
antagonist's perspective on,
1192-1201
protagonist's perspective on,
1189-1191

- Venlafaxine
for depression, 1072-1073
for hot flashes, 1103-1104
- Venous thromboembolism
calf, anticoagulants for, **1157-1164**
epidemiology of, 1160
femoral vein, hypercoagulable state testing in, **1237-1250**
iliofemoral, thrombolytic therapy for, **1165-1177**
in oral contraceptive use, thrombolytic therapy for, **1165-1177**
perioperative, **77-110**
asymptomatic
incidence of, 78
screening for, 95-96
bleeding risk assessment and, 82
epidemiology of, 77-78
in cancer, 247-248
long-term oral anticoagulation and, 96-100
mortality in, 77-78
overview of, 77-78
prophylaxis for
bleeding risk assessment in, 82-83
duration of, 94-95
efficacy of, 83
in brain tumor, **1179-1187**
in neurologic disease, 265-266
inferior vena cava filters in, 87
methods for, 83-84
nonpharmacologic, 83-87
pharmacologic, 87-93. *See also specific agents.*
postoperative, 101
safety of, 83
timing of, 93-94
risk for
assessment of, 79-82
stratification of, 82-83
prophylaxis for. *See also Venous thromboembolism, perioperative, prophylaxis for.*
in factor V Leiden heterozygosity, **1225-1236**
with inferior vena caval filter, **1189-1203**
risk of, in bridging therapy with heparin, 1212
warfarin for, precolonoscopy management in, **1205-1214**
- Ventricle(s)
left
aneurysm of, in CHF, surgery for, 529-530
dilatation of, in CHF, 308
dysfunction of, in CHF, asymptomatic, beta-blockers for, 359
filling time of, in CHF, resynchronization therapy effects on, 512
function of, in CHF, beta-blocker effects on, 349
hypertrophy of, in CHF, 305, 307-314
remodeling of, in CHF
Acorn cardiac support device effects on, 545-546
aldosterone effects on, 448-449
CardioClasp[®], 547
in left ventricular assist device support, 540-544
mitral valve repair effects on, 539-540
Myosplint[®] effects on, 546-547
MyoTech Cardiac Restoration System[®] effects on, 548
pathophysiology of, 524-527
resynchronization therapy effects on, 513
reshaping of (Dor procedure), for CHF, 530-534
right, myocardial infarction of, dobutamine for, 395
- Ventricular arrhythmias, perioperative, 143-147
- Ventricular resynchronization therapy. *See* Cardiac resynchronization therapy.
- Ventricular septum, dyskinesia of, in CHF, resynchronization therapy effects on, 512
- Ventriculectomy, left, partial (Batista operation), for CHF, 534-539
- Ventriculoperitoneal shunt, for normal pressure hydrocephalus, 797
- Verapamil, for hot flashes, 1106
- Verapamil, drug interactions with, beta-blockers, 359-360
- Vertebral fractures, in osteoporosis
epidemiology of, 1039-1040
prevention of. *See* Osteoporosis, treatment of.

- Vertebral fractures (*continued*)
 risk factors for, 1043
 surgical treatment of, 1055-1056
- Vertebral osteomyelitis, back pain in, 649-650
- Vertebrobasilar ischemia, dizziness in, 633, 762-764
- Vertebroplasty, in osteoporosis, 1055-1056
- Vertigo
 acute, 607-615
 in brainstem infarct, 611-614
 in inner ear infections, 607-611
 in vestibular schwannoma, 614-615
 benign paroxysmal, 623-627
 central positional, 627-629
- Vesnarinone, for CHF, 404, 407
- Vestibular nerve
 hypofunction of, dizziness in, 615-618
 neuritis of, dizziness in, 607-611, 798
- Vestibular schwannoma, dizziness in, 614-615
- Viral infections, acute autonomic neuropathy in, 852-853
- Vision, impairment of, in multiple sclerosis, 870-871
- Vitamin D
 deficiency of, osteoporosis in, 1040
 supplementation with, for osteoporosis, 1049
- Vitamin E, for hot flashes, 1108
- Vocal tics, in Tourette's syndrome, 771-773
- von Willebrand's disease, perioperative, 239
- Vulvovaginal atrophy, in menopause, 1029-1030
- Vulvovaginal candidiasis, in HIV infection, 978-979
- W**
- Wakefulness test, in sleep disorders, 809
- Warfarin
 for brainstem stroke, 613
 for calf deep venous thrombosis, 1159
 for popliteal vein thrombosis, precolonoscopy management of, 1205-1214
 perioperative, 45-46
 for thromboembolism prophylaxis, 89-90
 in long-term use, 96-100
- Warming, supplemental, for postoperative infection risk reduction, 60
- Wartenberg's sign, in ulnar neuropathy at elbow, 665
- Warts, genital, in HIV infection, 982
- Washed platelet assays, in heparin-induced thrombocytopenia, 1220-1221
- Water retention, in CHF. *See* Kidney, dysfunction/failure of, in CHF.
- Weakness
 in Bell's palsy, 700-703
 in Guillain-Barré syndrome, 709-711
 in myotonic muscular dystrophy, 901
 in narcolepsy, 814-815
 in peroneal neuropathy, at fibular neck, 677-679
 in porphyria, 716-720
 in psychogenic tremor, 770-780
 in ulnar neuropathy, at wrist, 668-670
- Westergren test, in temporal arteritis, 603-604
- Whiplash injury, 650-652
- White blood cell count, preoperative, 11-12
- White matter, ischemia of, dizziness in, 619-620
- White women
 health facts about, 943
 hot flashes in, 1094-1095
- Women's health
 breast cancer. *See* Breast cancer.
 cardiovascular risk, 955-969
 depression, 1065-1076
 doctor-patient communication, 1115-1145
 educational resources for, 1138-1140
 estrogen alternatives, 1091-1113
 gender-specific medicine for, 917-937
 HIV infection, 971-995
 multicultural considerations in. *See* Multicultural considerations, in women's health.
 osteoporosis, 1039-1063
 sexuality, 1077-1090
 urogenital complaints, hormone therapy for, 1029-1037
- Women's Health Initiative, 921, 1032-1034
- World Health Organization
 osteoporosis criteria of, 1041
 women's health policies of, 924

Wrist

- median neuropathy at (carpal tunnel syndrome), 661-664, 706-708
- ulnar neuropathy at, 668-670

Wrist drop

- in porphyria, 717
- in radial neuropathy, 670-673, 719-720

X

- X chromosome, in gender-specific medicine, 925-926

- Ximelagatran, for thromboembolism prophylaxis, 93

- Xipamid, for CHF, 479

Y

- Y chromosome, in gender-specific medicine, 925-926

Z

- Zaleplon, for insomnia, 818-819

- Zolmitriptan, for migraine headache, 594-596

- Zolpidem, for insomnia, 819

- Zonisamide, for epilepsy, 741